Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thiamine Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | TKT | P29401 | 11/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiamine Ion SCHEMBL7200449 | 1.00 | HSP90AA1 (0.95) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL1644252 | 1.00 | HSP90AA1 (0.95) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL41101 | 1.00 | HSP90AA1 (0.95) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL1251742 | 1.00 | HSP90AA1 (0.95) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL5317564 | 1.00 | HSP90AA1 (0.95) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL30028012 | 1.00 | HSP90AA1 (0.95) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL16085815 | 0.99 | HSP90AA1 (0.93) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL18879464 | 0.99 | HSP90AA1 (0.93) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL18167436 | 0.99 | HSP90AA1 (0.93) | HSP90AA1KDM4ETKTTDP1LMNA | |
| Thiamine Ion SCHEMBL28055245 | 0.99 | HSP90AA1 (0.93) | HSP90AA1KDM4ETKTTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1207 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243437-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTO TEQ, INC. (US) | 2025-07-31 | — | — | US | claimed |
| US-20250243436-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTO TEQ, INC. (US) | 2025-07-31 | — | — | US | claimed |
| EP-4482300-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | Phyto Teq, Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2024251908-A1 | COMPOSITION AND PROCESS FOR TREATING KERATIN FIBRES USING AT LEAST ONE PARTICULAR PYRIMIDINE DERIVATIVE AND AT LEAST ONE UNSATURATED FATTY ACID | L'OREAL (FR) | 2024-12-12 | — | — | WO | claimed |
| CN-118870969-A | Method for producing agave cultures for agave wine | 弗陶特克有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20240141264-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTOTEQ, INC. | 2024-05-02 | — | — | US | claimed |
| US-11895962-B2 | Method for producing agave cultures for tequila | PHYTOTEQ, INC. (US) | 2024-02-13 | — | — | US | claimed |
| WO-2023163747-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTOTEQ, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| US-20230263120-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTOTEQ, INC. (US) | 2023-08-24 | — | — | US | claimed |
| CN-116355773-A | Saccharomyces cerevisiae genetically engineered bacterium for producing succinic acid, construction method and application thereof | 杭州欧合生物科技有限公司 | 2023-06-30 | — | — | CN | claimed |
| EP-3551201-A1 | METHODS AND COMPOSITIONS RELATING TO ISOLATED AND PURIFIED MICROBES | Pendulum Therapeutics, Inc. (US) | 2019-10-16 | — | — | EP | claimed |
| US-10376601-B2 | In-vivo intravascular blood replacing liquid, in-vivo intravascular blood replacing liquid formulation, and prefilled syringe | TERUMO KABUSHIKI KAISHA (JP) | 2019-08-13 | — | — | US | claimed |
| WO-2018106844-A1 | METHODS AND COMPOSITIONS RELATING TO ISOLATED AND PURIFIED MICROBES | WHOLE BIOME INC. (US) | 2018-06-14 | — | — | WO | claimed |
| US-9555063-B2 | Pluripotent therapeutic compositions and uses thereof | IMMUNOPATH PROFILE, INC. (US) | 2017-01-31 | — | — | US | claimed |
| WO-2016079576-A1 | A PROCESS FOR THE PREPARATION OF A THIAMINE DERIVATIVE AND SALT THEREOF | ASHMI LIFE SCIENCES PRIVATE LIMITED (IN) | 2016-05-26 | — | — | WO | claimed |
| US-20140193368-A1 | PLURIPOTENT THERAPEUTIC COMPOSITIONS AND USES THEREOF | IMMUNOPATH PROFILE, INC. (US) | 2014-07-10 | — | — | US | claimed |
| US-20090274660-A1 | Synthetic Stem Cell-like Tissue Healing and Regeneration Medication; nutraceuticals; glycosaminoglycan, polar surface active lipid such as lecithin, enantiomerically pure L-amino acids and glycine, vitamins, sorbitan fatty esters or grapeseed extract | IMMUNOPATH PROFILE, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-6903134-B2 | Formulation comprising benzofuranone derivatives for protection against oxidative stress | MERCK PATENT GMBH (DE) | 2005-06-07 | — | — | US | claimed |
| EP-1100453-B1 | COSMETIC FORMULATION CONTAINING ECTOINE DERIVATIVES, ENZYMES, VITAMINS AND/OR VITAMIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-01-05 | — | — | EP | claimed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12628856-B2 | Nutritional composition having lipophilic compounds with improved solubility and bioavailability | ABBOTT LABORATORIES (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130975-A1 | INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF | PROTHERA BIOLOGICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12618029-B2 | Method for producing agave cultures for tequila | PHYTOTEQ, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12605343-B2 | Method for producing microbubble-containing electrolyte solution and method for producing microbubble-containing solvent used for preparing microbubble-containing electrolyte solution | AICHI MEDICAL UNIVERSITY (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4234546-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12583854-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4048671-B1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | AMGEN INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4707402-A1 | BIOELECTROCHEMICAL HYDROXYLATION OF SUBSTRATES USING FUNCTIONAL WATER-DEPENDENT ALKYL-HYDROXYLASE HYBRID ELECTRODES AND RESPECTIVE BIOFILM HYBRID ELECTRODES | Albert-Ludwigs-Universität Freiburg Körperschaft des öffentlichen Rechts (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-3592329-B1 | USE OF COMPATIBLE SOLUTES | SUSONITY Commercial GmbH (DE) | 2026-02-18 | — | — | EP | disclosed |
| US-12544412-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | PENDULUM THERAPEUTICS INC (US) | 2026-02-10 | — | — | US | disclosed |
| US-12540129-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4684786-A2 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4685160-A2 | COMBINATION THERAPY INCLUDING A KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260007665-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12509442-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4058453-B1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3883579-B1 | COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4007756-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368643-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250368642-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3503866-B1 | COMPOSITIONS COMPRISING ISOHEXIDE DIESTERS OF C18 FATTY ACIDS AND THEIR USE IN METHODS FOR RESTORING EPIDERMAL INTEGRITY AND FUNCTION AND TREATING DERMATOLOGICAL DISEASES | SYTHEON LTD (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250362134-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-12473281-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12466825-B2 | Synthesis of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250325527-A1 | KIF18A INHIBITION FOR TREATMENT OF CANCER | AMGEN INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12441705-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12441736-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12435058-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4007753-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4007752-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250290081-A1 | MICROORGANISMS FOR DITERPENE PRODUCTION | CARGILL, INCORPORATED | 2025-09-18 | — | — | US | disclosed |
| EP-3718417-B1 | STEVIOL GLYCOSIDES | DSM IP ASSETS BV (NL) | 2025-09-03 | — | — | EP | disclosed |
| EP-4007561-B1 | PREVENTION AND REDUCTION OF CORNIFICATION DISORDERS AND RELATED COSMETIC AGENTS | MERCK PATENT GMBH (DE) | 2025-08-27 | — | — | EP | disclosed |
| US-12391691-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-12391689-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250243437-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTO TEQ, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250241868-A1 | METHODS OF TREATING CANCER USING THIOREDOXIN REDUCTASE INHIBITORS | FATHER FLANAGAN'S BOYS' HOME DOING BUSINESS AS BOYS TOWN NATIONAL RESEARCH HOSPITAL | 2025-07-31 | — | — | US | disclosed |
| US-20250243436-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTO TEQ, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-2498772-B1 | COMPOSITION AND METHODS FOR IMPROVING SKIN APPEARANCE | SYTHEON LTD (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250206735-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250206736-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250179068-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2025105379-A1 | COMPOSITION FOR FEEDING DETERRING METHOD OR FOR FEEDING DETERRENCE, BODY WEIGHT REDUCTION, FATTY LIVER IMPROVEMENT AND BODY FAT REDUCTION | 国立大学法人大阪大学 | 2025-05-22 | — | — | WO | disclosed |
| US-12280056-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4534116-A1 | COLLAGEN-RICH ORGANIC COMPOSITION AND PRODUCTION METHOD THEREOF | Devine Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| EP-4529950-A2 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT | Pendulum Therapeutics, Inc. (US) | 2025-04-02 | — | — | EP | disclosed |
| EP-4515234-A1 | KIF18A INHIBITION FOR TREATMENT OF CANCER | Amgen Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-119391735-A | Expression of naturally secreted polypeptides without signal peptide | 诺维信公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-3881680-B1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT | PENDULUM THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-3885443-B1 | DITERPENE PRODUCTION | DSM IP ASSETS BV (NL) | 2025-01-15 | — | — | EP | disclosed |
| EP-4486361-A1 | COSMETIC USE OF A COMPOSITION COMPRISING AN AQUEOUS SEAWEED EXTRACT OF PELVETIA CANALICULATA FOR INCREASING GLOSS OF SKIN | Merck Patent GmbH (DE) | 2025-01-08 | — | — | EP | disclosed |
| US-12185684-B2 | Method of production of phytocannabinoids for use in medical treatments | CELL SCIENCE HOLDING LTD (CY) | 2025-01-07 | — | — | US | disclosed |
| US-20250000843-A1 | LIGNAN-INSPIRED COMPOUNDS, METHODS OF MAKING, AND USING THEREOF | IOWAIBO, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4482300-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | Phyto Teq, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240408089-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024251908-A1 | COMPOSITION AND PROCESS FOR TREATING KERATIN FIBRES USING AT LEAST ONE PARTICULAR PYRIMIDINE DERIVATIVE AND AT LEAST ONE UNSATURATED FATTY ACID | L'OREAL (FR) | 2024-12-12 | — | — | WO | disclosed |
| US-12161675-B2 | Production method for culture supernatant preparation | LABORATORY OF CELL APPLIED TECHNOLOGIES, CO (JP) | 2024-12-10 | — | — | US | disclosed |
| CN-118870969-A | Method for producing agave cultures for agave wine | 弗陶特克有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3898592-B1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240327384-A1 | SALTS AND SOLID STATE FORMS OF A KIF18A INHIBITOR COMPOUND | AMGEN INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3898616-B1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240317715-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240307466-A1 | Methods and Compositions Relating to Microbial Treatment and Diagnosis of Disorders | Pendulum Therapeutics, Inc. | 2024-09-19 | — | — | US | disclosed |
| CN-118652942-A | Fermentation process | 德希尼布能源法国公司 | 2024-09-17 | — | — | CN | disclosed |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240287068-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4420525-A1 | COMPOSITION USED TO PREVENT OR SUPPRESS REFEEDING SYNDROME | Otsuka Pharmaceutical Factory, Inc. (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-12054476-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240254100-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240245686-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4403175-A2 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3788053-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3756642-B1 | METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES | MERCK PATENT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-12012416-B2 | Compositions and methods for treating atopic dermatitis | SYTHEON LTD (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240190862-A1 | EPOXYAMIDES AS KRAS G12C AND KRAS G12D INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240173328-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4373818-A1 | SALTS AND SOLID STATE FORMS OF A KIF18A INHIBITOR COMPOUND | AMGEN INC. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11993597-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-11976074-B1 | Crystalline salts of Linsitinib | Sling Therapeutics, Inc. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240139193-A1 | COMBINATION THERAPY OF KRAS INHIBITOR AND SHP2 INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240141264-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTOTEQ, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11970435-B2 | Taste-modified creatine salts, compounds, compositions and uses thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| CN-116744973-B | Gel-like nutritional composition | EN大冢制药株式会社 | 2024-04-09 | — | — | CN | disclosed |
| EP-4141005-B1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC (US) | 2024-04-03 | — | — | EP | disclosed |
| WO-2024064327-A1 | HUMAN MILK OLIGOSACCHARIDES FOR ENHANCING BLOOD-BRAIN BARRIER FUNCTION | ABBOTT LABORATORIES (US) | 2024-03-28 | — | — | WO | disclosed |
| US-11931387-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082251-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | AMGEN INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240081209-A1 | A METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | CELL SCIENCE HOLDING LTD (CY) | 2024-03-14 | — | — | US | disclosed |
| US-11918584-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11903990-B2 | Compositions and methods for treating and removing seborrheic keratoses | STOECKER WILLIAM VAN DOVER (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-11895962-B2 | Method for producing agave cultures for tequila | PHYTOTEQ, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11890372-B2 | Transfusion preparation | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-114364267-B | Novel flavor composition, preparation method and application thereof | 国际香料和香精公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| WO-2024004981-A1 | COLLAGEN-RICH ORGANIC COMPOSITION AND PRODUCTION METHOD THEREOF | 株式会社DeVine | 2024-01-04 | — | — | WO | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023212714-A1 | KIF18A INHIBITION FOR TREATMENT OF CANCER | AMGEN INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4268898-A2 | KRAS G12C INHIBITORS FOR TREATING CANCER | Amgen Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| CN-115337283-B | Nano-encapsulation object for encapsulating adenosine by molecular motor vesicle, preparation method, composition and application of composition | 时垠(上海)生物科技有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116744973-A | Gel-like nutritional composition | EN大冢制药株式会社 | 2023-09-12 | — | — | CN | disclosed |
| US-11753415-B2 | Compositions and methods for treating atopic dermatitis | SYTHEON LTD (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753414-B2 | Compositions and methods for treating atopic dermatitis | SYTHEON LTD (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023161415-A1 | COSMETIC USE OF A COMPOSITION COMPRISING AN AQUEOUS SEAWEED EXTRACT OF PELVETIA CANALICULATA FOR INCREASING GLOSS OF SKIN | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| US-20230270151-A1 | NUTRITIONAL COMPOSITION HAVING LIPOPHILIC COMPOUNDS WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | ABBOTT LABORATORIES | 2023-08-31 | — | — | US | disclosed |
| WO-2023163747-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTOTEQ, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-4234546-A2 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11737997-B2 | Method to increase cellular availability of calcium in skin cells and mixtures | MERCK PATENT GMBH (DE) | 2023-08-29 | — | — | US | disclosed |
| US-20230263120-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTOTEQ, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230263858-A1 | NUTRITION FORMULATION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230263205-A1 | METHOD FOR PRODUCING SUGAR FROM AGAVE CULTURES | PHYTOTEQ, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230248729-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | AMGEN INC (US) | 2023-08-10 | — | — | US | disclosed |
| CN-111867605-B | Infusion preparation | 株式会社大塚制药工场 | 2023-07-25 | — | — | CN | disclosed |
| US-11690335-B2 | Method of production of phytocannabinoids for use in medical treatments | CELL SCIENCE HOLDING LTD (CY) | 2023-07-04 | — | — | US | disclosed |
| CN-116355773-A | Saccharomyces cerevisiae genetically engineered bacterium for producing succinic acid, construction method and application thereof | 杭州欧合生物科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230192682-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192681-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2023-06-22 | — | — | US | disclosed |
| EP-3880670-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3897855-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4190324-A1 | NUTRITION FORMULATION | Otsuka Pharmaceutical Factory, Inc. (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-20230167126-A1 | Compositions and Methods for Treating Atopic Dermatitis | SYTHEON LTD (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167125-A1 | Compositions and Methods for Treating Atopic Dermatitis | SYTHEON LTD (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230110463-A1 | METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | CELL SCIENCE HOLDING LTD (CY) | 2023-04-13 | — | — | US | disclosed |
| US-20230114071-A1 | NUTRITIONAL COMPOSITION HAVING LIPOPHILIC COMPOUNDS WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | ABBOTT LABORATORIES | 2023-04-13 | — | — | US | disclosed |
| CN-109689864-B | Malate dehydrogenase | 帝斯曼知识产权资产管理有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115024989-B | Liposome-molecular motor stabilizer solution with curcumin or tetrahydrocurcumin coated by molecular motor vesicles, and preparation method and application thereof | 浙江迪恩生物科技股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-4141005-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4136263-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | Amgen Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115667551-A | KIF18A inhibitors for the treatment of neoplastic diseases | 美国安进公司 | 2023-01-31 | — | — | CN | disclosed |
| US-11564924-B2 | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound | RENASCIENCE CO., LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| WO-2023004075-A1 | SALTS AND SOLID STATE FORMS OF A KIF18A INHIBITOR COMPOUND | AMGEN INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20230024972-A1 | BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF | PHYTO TECH CORP D/B/A/ BLUE CALIFORNIA CO (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028414-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | AMGEN INC. | 2023-01-26 | — | — | US | disclosed |
| CN-115626923-A | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20230020348-A1 | GALACTOOLIGOSACCHARIDES FOR PREVENTING INJURY AND/OR PROMOTING HEALING OF THE GASTROINTESTINAL TRACT | ABBOTT LABORATORIES | 2023-01-19 | — | — | US | disclosed |
| CN-111051306-B | Inhibitors of KRAS G12C and methods of use thereof | 美国安进公司 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022266493-A1 | BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF | PHYTO TECH CORP D/B/A/ BLUE CALIFORNIA CO (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-3394251-B1 | HOST CELLS FOR DICARBOXYLIC ACID PRODUCTION | DSM IP ASSETS BV (NL) | 2022-12-21 | — | — | EP | disclosed |
| US-20220395541-A1 | Methods and Compositions Comprising a Bacteria with Increased Viability and Faster Revivability | Pendulum Therapeutics, Inc. | 2022-12-15 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3802535-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387333-A1 | Manufacturing Method for Microbubble-Containing Electrolyte and Manufacturing Method for Microbubble-Containing Solvent for Use in Preparing Microbubble-Containing Electrolyte | AICHI MEDICAL UNIVERSITY (JP) | 2022-12-08 | — | — | US | disclosed |
| US-20220378787-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. (US) | 2022-12-01 | — | — | US | disclosed |
| EP-4095230-A1 | GENETICALLY MODIFIED YEAST FOR THE BIOTECHNOLOGICAL PRODUCTION OF SUCCINIC ACID FROM GLYCEROL | Jacobs University Bremen gGmbH (DE) | 2022-11-30 | — | — | EP | disclosed |
| US-20220372018-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-11-24 | — | — | US | disclosed |
| CN-110997668-B | KRAS G12C inhibitors and methods of use thereof | 美国安进公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11477953-B2 | Method of production of phytocannabinoids for use in medical treatments | CELL SCIENCE HOLDING LTD. (CY) | 2022-10-25 | — | — | US | disclosed |
| EP-4058432-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058453-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11446316-B2 | Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract | ABBOTT LABORATORIES (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220289724-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11439645-B2 | Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2022-09-13 | — | — | US | disclosed |
| CN-115024989-A | Liposome prepared by coating curcumin or tetrahydrocurcumin with molecular motor vesicle and preparation method and application thereof | 浙江迪恩生物科技股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220281843-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-09-08 | — | — | US | disclosed |
| EP-4048671-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-11426404-B2 | Dosing of KRAS inhibitor for treatment of cancers | AMGEN INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220264921-A1 | NOVEL FLAVOR COMPOSITION AND METHODS OF PREPARATION AND USES THEREOF | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-4045047-A1 | COMBINATION THERAPY OF KRAS INHIBITOR AND SHP2 INHIBITOR FOR TREATMENT OF CANCERS | Amgen Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4043077-A1 | MANUFACTURING METHOD FOR MICROBUBBLE-CONTAINING ELECTROLYTE AND MANUFACTURING METHOD FOR MICROBUBBLE-CONTAINING SOLVENT FOR USE IN PREPARING MICROBUBBLE-CONTAINING ELECTROLYTE | Aichi Medical University (JP) | 2022-08-17 | — | — | EP | disclosed |
| US-20220251103-A1 | Compositions and Methods for Treating Atopic Dermatitis | SYTHEON LTD (US) | 2022-08-11 | — | — | US | disclosed |
| WO-2022163760-A1 | GEL-LIKE NUTRITIONAL COMPOSITION | イーエヌ大塚製薬株式会社 | 2022-08-04 | — | — | WO | disclosed |
| EP-3679040-B1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-11400144-B2 | Complete genome sequence of the methanogen Methanobrevibacter ruminantium | PASTORAL GREENHOUSE GAS RESEARCH LTD. (NZ) | 2022-08-02 | — | — | US | disclosed |
| CN-114761427-A | Methods and compositions for modulating the glycosylation profile of proteins | 默克专利股份公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220220112-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2022-07-14 | — | — | US | disclosed |
| CN-114728960-A | Improved synthesis of KRAS G12C inhibitor compounds | 美国安进公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220213101-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2022-07-07 | — | — | US | disclosed |
| EP-2533753-B1 | SUNSCREEN COMPOSITIONS COMPRISING UNIFORM, RIGID, SPHERICAL, NANOPOROUS CALCIUM PHOSPHATE PARTICLES, AND METHODS OF MAKING AND USING THE SAME | LABORATORY SKIN CARE INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11364270-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022124243-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | 東和薬品株式会社 | 2022-06-16 | — | — | WO | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| EP-4007561-A1 | PREVENTION AND REDUCTION OF CORNIFICATION DISORDERS AND RELATED COSMETIC AGENTS | Merck Patent GmbH (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-4007752-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4007756-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4007753-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-4007638-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | Amgen Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| US-20220167577-A1 | METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | CELL SCIENCE HOLDING LTD (CY) | 2022-06-02 | — | — | US | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001424-A1 | SYNTHESIS OF 25-HYDROXY-VITAMIN D3, 25-HYDROXY-7-DEHYDROCHOLESTEROL AND ANALOGOUS ALCOHOLS USING THE BETA-PROTEOBACTERIUM THAUERA AROMATICA | Albert-Ludwigs-Universität Freiburg (DE) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022101282-A1 | SYNTHESIS OF 25-HYDROXY-VITAMIN D3, 25-HYDROXY-7-DEHYDROCHOLESTEROL AND ANALOGOUS ALCOHOLS USING THE BETA-PROTEOBACTERIUM THAUERA AROMATICA | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2022-05-19 | — | — | WO | disclosed |
| EP-3996524-A1 | NOVEL FLAVOR COMPOSITION AND METHODS OF PREPARATION AND USES THEREOF | International Flavors and Fragrances Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20220133828-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | STOECKER WILLIAM VAN DOVER (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022090277-A1 | N-FUNCTIONALIZED FATTY ACID AMIDES AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| US-11312725-B2 | Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases | SYTHEON LIMITED (US) | 2022-04-26 | — | — | US | disclosed |
| CN-114401953-A | KIF18A inhibitors | 美国安进公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114391012-A | Pyridine derivatives as KIF18A inhibitors | 美国安进公司 | 2022-04-22 | — | — | CN | disclosed |
| US-11306087-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| CN-114364267-A | Novel flavor composition, preparation method and application thereof | 国际香料和香精公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114302880-A | KIF18A inhibitors | 美国安进公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220106293-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3977999-A1 | TREATMENT OF PHENYLKETONURIA WITH BH4 | BioMarin Pharmaceutical Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114269731-A | KIF18A inhibitors | 美国安进公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3974429-A1 | PRECURSORS OF KRAS G12C INHIBITORS | Amgen Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3968998-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | Amgen, Inc (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11278580-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2022-03-22 | — | — | US | disclosed |
| CN-114206300-A | Preventing and reducing keratinization disorder and related cosmetic | 默克专利股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220056015-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11253519-B2 | Composition used to improve symptoms of autism spectrum disorder, and method using same for improving symptoms of autism spectrum disorder | RENASCIENCE CO., LTD. (JP) | 2022-02-22 | — | — | US | disclosed |
| US-20220031646-A1 | Dietary Supplements and Composition for Treating Cancer | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-02-03 | — | — | US | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11234914-B2 | Monosubstituted urea derivatives as a self-tanning substance | MERCK PATENT GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| WO-2022018462-A1 | CATECHOL BASED DERIVATIVES FOR USE IN THE PREVENTION OF DNA DAMAGE | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2022-01-27 | — | — | WO | disclosed |
| EP-3138566-B1 | TREATMENT OF PHENYLKETONURIA WITH BH4 | BIOMARIN PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002298-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-01-06 | — | — | US | disclosed |
| US-20220002311-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-01-06 | — | — | US | disclosed |
| US-11213556-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| CN-113840606-A | Treatment of cancer by administration of KRAS inhibitors | 美国安进公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20210386798-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | Pendulum Therapeutics, Inc. | 2021-12-16 | — | — | US | disclosed |
| EP-3919615-A1 | MALATE DEHYROGENASES | DSM IP Assets B.V. (NL) | 2021-12-08 | — | — | EP | disclosed |
| CN-113730442-A | Methods and compositions relating to microbial treatment and diagnosis of disorders | 潘德勒姆治疗公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3630761-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-107847549-B | Methods for increasing glutathione levels in cells | 默克专利股份公司 | 2021-11-16 | — | — | CN | disclosed |
| US-11160817-B2 | Nutritional compositions comprising neuroprotective dietary oligosaccharides | ABBOTT LABORATORIES (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3898616-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897852-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897855-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898592-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021211549-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-11147784-B2 | Dietary supplements and composition for treating cancer | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3883579-A2 | <SUP2/>? <SUB2/>?G12C? ?COMBINATION THERAPY INCLUDING A KRASINHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3885443-A1 | DITERPENE PRODUCTION | DSM IP Assets B.V. (NL) | 2021-09-29 | — | — | EP | disclosed |
| EP-3881680-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT | Pendulum Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880670-A1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | Amgen Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3485004-B1 | MALATE DEHYROGENASES | DSM IP ASSETS BV (NL) | 2021-09-22 | — | — | EP | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113226473-A | KIF18A inhibitors | 美国安进公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11053226-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-113038953-A | Comprising KRAS for the treatment of cancerG12CCombination therapy of an inhibitor and one or more other pharmaceutically active agents | 美国安进公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2021126816-A1 | DOSING REGIMEN OF A KRAS G12C INHIBITOR | AMGEN INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| CN-113015724-A | Improved synthesis of key intermediates of KRAS G12C inhibitor compounds | 美国安进公司 | 2021-06-22 | — | — | CN | disclosed |
| WO-2021097207-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021097212-A1 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021084869-A1 | MANUFACTURING METHOD FOR MICROBUBBLE-CONTAINING ELECTROLYTE AND MANUFACTURING METHOD FOR MICROBUBBLE-CONTAINING SOLVENT FOR USE IN PREPARING MICROBUBBLE-CONTAINING ELECTROLYTE | 学校法人 愛知医科大学 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021081212-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | AMGEN INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-3810073-A1 | SKIN LIGHTENING COMPOSITIONS AND METHODS | Sytheon Limited (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2021076655-A1 | COMBINATION THERAPY OF KRAS INHIBITOR AND SHP2 INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-3807276-A2 | KRAS G12C INHIBITORS ENCOMPASSING A PIPERAZINE RING AND USE THEREOF IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3802535-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3802537-A1 | KRAS G12C INHIBITORS FOR TREATING CANCER | Amgen Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10960063-B2 | Complete genome sequence of the methanogen Methanobrevibacter ruminantium | PASTORAL GREENHOUSE GAS RESEARCH LTD. (NZ) | 2021-03-30 | — | — | US | disclosed |
| EP-3021689-B1 | DITERPENE PRODUCTION | DSM IP ASSETS BV (NL) | 2021-03-24 | — | — | EP | disclosed |
| US-20210077370-A1 | Use of compositions comprising dihydroxyacetone for the protection of skin or hair against infrared irradiation | MERCK PATENT GMBH (DE) | 2021-03-18 | — | — | US | disclosed |
| EP-3790886-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3791854-A1 | USE OF COMPOSITIONS COMPRISING DIHYDROXYACETONE FOR THE PROTECTION OF SKIN OR HAIR AGAINST INFRARED IRRADIATION | Merck Patent GmbH (DE) | 2021-03-17 | — | — | EP | disclosed |
| EP-3788053-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| WO-2021026101-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021026099-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021026098-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021026100-A1 | PYRIDINE DERIVATIVES AS KIF18A INHIBITORS | AMGEN INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-10912323-B2 | Nutritional supplement powder | ABBOTT LABORATORIES (US) | 2021-02-09 | — | — | US | disclosed |
| CN-112334144-A | Method for producing culture supernatant preparation | 株式会社细胞应用技术研究所 | 2021-02-05 | — | — | CN | disclosed |
| WO-2021018990-A1 | PREVENTION AND REDUCTION OF CORNIFICATION DISORDERS AND RELATED COSMETIC AGENTS | MERCK PATENT GMBH (DE) | 2021-02-04 | — | — | WO | disclosed |
| EP-3766504-A1 | TRANSFUSION PREPARATION | Otsuka Pharmaceutical Factory, Inc. (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-10893675-B2 | Powder formulation containing insect repellent | MERCK PATENT GMBH (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210007975-A1 | TRANSFUSION PREPARATION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2021-01-14 | — | — | US | disclosed |
| WO-2021007476-A1 | NOVEL FLAVOR COMPOSITION AND METHODS OF PREPARATION AND USES THEREOF | INTERNATIONAL FLAVORS AND FRAGRANCES INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20210000829-A1 | PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND | RENASCIENCE CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
| US-20200405674-A1 | METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES | MERCK PATENT GMBH (DE) | 2020-12-31 | — | — | US | disclosed |
| EP-3756642-A1 | METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES | Merck Patent GmbH (DE) | 2020-12-30 | — | — | EP | disclosed |
| CN-112143762-A | Fermentation process | 帝斯曼知识产权资产管理有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-10857077-B2 | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200368233-A1 | COMPOSITION USED TO IMPROVE SYMPTOMS OF AUTISM SPECTRUM DISORDER, AND METHOD USING SAME FOR IMPROVING SYMPTOMS OF AUTISM SPECTRUM DISORDER | RENASCIENCE CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| US-10842830-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10842831-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020232130-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200360374-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | AMGEN INC. (US) | 2020-11-19 | — | — | US | disclosed |
| EP-3738593-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | Amgen, Inc (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10828241-B2 | Skin lightening compositions and methods | SYTHEON LIMITED (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200345796-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | TRINITY CAPITAL INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200339532-A1 | PDE4D INHIBITORS | TETRA DISCOVERY PARTNERS, INC. | 2020-10-29 | — | — | US | disclosed |
| EP-3718417-A1 | STEVIOL GLYCOSIDES | DSM IP Assets B.V. (NL) | 2020-10-07 | — | — | EP | disclosed |
| US-10779550-B2 | Human milk oligosaccharides to ameliorate symptoms of stress | ABBOTT LABORATORIES (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3700326-A1 | A METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | Cell Science Holding Ltd (CY) | 2020-09-02 | — | — | EP | disclosed |
| US-20200261517-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | TRINITY CAPITAL INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200261518-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | TRINITY CAPITAL INC. | 2020-08-20 | — | — | US | disclosed |
| US-20200239441-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10722441-B2 | Noreugenin glycoside derivatives | UNIVERSITAET HAMBURG (DE) | 2020-07-28 | — | — | US | disclosed |
| CN-111465322-A | Process for the preparation of phytocannabinoids for medical use | 细胞科学控股有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20200230162-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2020-07-23 | — | — | US | disclosed |
| US-10717729-B2 | Thiamine-organic acid salt | PURDUE RESEARCH FOUNDATION (US) | 2020-07-21 | — | — | US | disclosed |
| US-20200222407-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| EP-3679040-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200216446-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2020-07-09 | — | — | US | disclosed |
| EP-3277829-B1 | STEVIOL GLYCOSIDES | DSM IP ASSETS BV (NL) | 2020-07-08 | — | — | EP | disclosed |
| EP-3002334-B1 | METHOD FOR THE PRODUCTION OF BIOPRODUCTS | NATURALLY SCIENTIFIC TECH LIMITED (GB) | 2020-07-08 | — | — | EP | disclosed |
| US-20200207766-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200199526-A1 | METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | CELL SCIENCE HOLDING LTD (CY) | 2020-06-25 | — | — | US | disclosed |
| US-20200196548-A1 | METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | CELL SCIENCE HOLDING LTD (CY) | 2020-06-25 | — | — | US | disclosed |
| WO-2020132651-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132649-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132653-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132648-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200181162-A1 | COMPOSITIONS AND METHODS FOR RESTORING EPIDERMAL INTEGRITY AND FUNCTION AND TREATING DERMATOLOGICAL DISEASES | SYTHEON LIMITED (US) | 2020-06-11 | — | — | US | disclosed |
| US-10675312-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10668116-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | Pendulum Therapeutics, Inc. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200165231-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-05-28 | — | — | US | disclosed |
| US-10660925-B2 | Method for producing a medium containing steroidal glycosides from plant cells of the genus Hoodia | LYKKE RESEARCH LIMITED (GB) | 2020-05-26 | — | — | US | disclosed |
| WO-2020102730-A1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148632-A1 | TASTE-MODIFIED CREATINE SALTS, COMPOUNDS, COMPOSITIONS AND USES THEREOF | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10639319-B2 | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract | ABBOTT LABORATORIES (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640504-B2 | Inhibitors of KRAS G12C and methods of using the same | AMGEN INC. (US) | 2020-05-05 | — | — | US | disclosed |
| CN-111093667-A | Solid preparation containing vitamin B1 | 武田消费保健株式会社 | 2020-05-01 | — | — | CN | disclosed |
| US-20200121738-A1 | METHODS AND COMPOSITIONS RELATING TO ISOLATED AND PURIFIED MICROBES | Pendulum Therapeutics, Inc. | 2020-04-23 | — | — | US | disclosed |
| US-10624916-B2 | Nutritional formulations using human milk oligosaccharides for modulating inflammation | ABBOTT LABORATORIES (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200108131-A1 | COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHANOBREVIBACTER RUMINANTIUM | PASTORAL GREENHOUSE GAS RESEARCH LTD. (NZ) | 2020-04-09 | — | — | US | disclosed |
| EP-3630761-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10597402-B2 | Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases | SYTHEON LIMITED (US) | 2020-03-24 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200060111-A1 | METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | CELL SCIENCE HOLDING LTD (CY) | 2020-02-27 | — | — | US | disclosed |
| US-20200060949-A1 | Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | LABORATORY SKIN CARE, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2020027336-A1 | PRODUCTION METHOD FOR CULTURE SUPERNATANT PREPARATION | 株式会社細胞応用技術研究所 | 2020-02-06 | — | — | WO | disclosed |
| US-20200038304-A1 | MONOSUBSTITUTED UREA DERIVATIVES AS A SELF-TANNING SUBSTANCE | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200038306-A1 | BARBITURIC ACID DERIVATIVES AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200030324-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200030214-A1 | USE OF COMPATIBLE SOLUTES | MERCK PATENT GMBH (DE) | 2020-01-30 | — | — | US | disclosed |
| CN-105342995-B | Infusion preparation | 株式会社大塚制药工场 | 2020-01-21 | — | — | CN | disclosed |
| CN-110679948-A | Nutritional formulations for modulating inflammation using human milk oligosaccharides | 雅培制药有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| EP-3043658-B1 | NUTRITIONAL COMPOSITION HAVING LIPOPHILIC COMPOUNDS WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | ABBOTT LAB (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10477791-B2 | Method of production of phytocannabinoids for use in medical treatments | CELL SCIENCE HOLDING LTD. (CY) | 2019-11-19 | — | — | US | disclosed |
| WO-2019217691-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190336514-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-07 | — | — | US | disclosed |
| EP-2934189-B1 | HUMAN MILK OLIGOSACCHARIDES TO AMELIORATE SYMPTOMS OF STRESS | ABBOTT LAB (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10465215-B2 | Production of biofuel from tissue culture sources | NATURALLY SCIENTIFIC TECHNOLOGIES LIMITED (GB) | 2019-11-05 | — | — | US | disclosed |
| US-20190328021-A1 | NUTRITIONAL SUPPLEMENT POWDER | ABBOTT LABORATORIES (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3558955-A2 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-110366550-A | Benzoisothiazole, isothiazolo [3,4-b ] pyridine, quinazoline, phthalazine, pyrido [2,3-d ] pyridazine and pyrido [2,3-d ] pyrimidine derivatives as KRAS G12C inhibitors for the treatment of lung, pancreatic or colorectal cancer | 美国安进公司 | 2019-10-22 | — | — | CN | disclosed |
| EP-3551201-A1 | METHODS AND COMPOSITIONS RELATING TO ISOLATED AND PURIFIED MICROBES | Pendulum Therapeutics, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| WO-2019189714-A1 | COMPOSITION | 興和株式会社 | 2019-10-03 | — | — | WO | disclosed |
| WO-2019176996-A1 | TRANSFUSION PREPARATION | 株式会社大塚製薬工場 | 2019-09-19 | — | — | WO | disclosed |
| US-20190274300-A1 | PRESERVATIVE SOLUTION FOR LIVE CELLS OR COMPOSITION CONTAINING LIVE CELLS | TERUMO KABUSHIKI KAISHA (JP) | 2019-09-12 | — | — | US | disclosed |
| US-20190275088-A1 | PRESERVATIVE SOLUTION FOR LIVE CELLS OR COMPOSITION CONTAINING LIVE CELLS | TERUMO KABUSHIKI KAISHA (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3536697-A1 | RECOVERY OF STEVIOL GLYCOSIDES | DSM IP Assets B.V. (NL) | 2019-09-11 | — | — | EP | disclosed |
| EP-3530729-A1 | PRESERVATIVE SOLUTION FOR LIVE CELLS OR COMPOSITION COMPRISING LIVE CELLS | Terumo Kabushiki Kaisha (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-3527077-A1 | PRESERVATIVE SOLUTION FOR LIVE CELLS OR COMPOSITION COMPRISING LIVE CELLS | Terumo Kabushiki Kaisha (JP) | 2019-08-21 | — | — | EP | disclosed |
| EP-3522863-A1 | BARBITURIC ACID DERIVATIVES AS SELF-TANNING SUBSTANCES | Merck Patent GmbH (DE) | 2019-08-14 | — | — | EP | disclosed |
| EP-3522993-A1 | MONOSUBSTITUTED UREA DERIVATIVES AS A SELF-TANNING SUBSTANCE | Merck Patent GmbH (DE) | 2019-08-14 | — | — | EP | disclosed |
| US-10376601-B2 | In-vivo intravascular blood replacing liquid, in-vivo intravascular blood replacing liquid formulation, and prefilled syringe | TERUMO KABUSHIKI KAISHA (JP) | 2019-08-13 | — | — | US | disclosed |
| EP-3210598-B1 | INFUSION PREPARATION | OTSUKA PHARMA FACTORY INC (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20190209503-A1 | Dietary Supplements and Composition for Treating Cancer | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2019-07-11 | — | — | US | disclosed |
| US-10342244-B2 | Infant formulas containing docosahexaenoic acid and lutein | ABBOTT LABORATORIES (US) | 2019-07-09 | — | — | US | disclosed |
| EP-3024941-B1 | DITERPENE PRODUCTION IN YARROWIA | DSM IP ASSETS BV (NL) | 2019-07-03 | — | — | EP | disclosed |
| EP-3503866-A1 | COMPOSITIONS AND METHODS FOR RESTORING EPIDERMAL INTEGRITY AND FUNCTION AND TREATING DERMATOLOGICAL DISEASES | Sytheon Limited (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190191646-A1 | METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTS | CELL SCIENCE HOLDING LTD (CY) | 2019-06-27 | — | — | US | disclosed |
| US-10314895-B2 | Complete genome sequence of the methanogen Methanobrevibacter ruminantium | PASTORAL GREENHOUSE GAS RESEARCH LTD. (NZ) | 2019-06-11 | — | — | US | disclosed |
| EP-2259768-B1 | COMPOSITIONS CONTAINING CYCLIC PEPTIDES AND METHODS OF USE | MERCK PATENT GMBH (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-10278911-B2 | Compositions containing cyclic peptides and methods of use | MERCK PATENT GMBH (DE) | 2019-05-07 | — | — | US | disclosed |
| US-10280439-B2 | Fermentation process for production of a dicarboxylic acid using fungal cells | DSM IP ASSESTS B.V. (NL) | 2019-05-07 | — | — | US | disclosed |
| US-10273519-B2 | Diterpene production in Yarrowia | DSM IP ASSETS B.V. (NL) | 2019-04-30 | — | — | US | disclosed |
| EP-2689014-B1 | HOST CELLS AND METHODS FOR PRODUCTION OF ISOBUTANOL | BUTAMAX TM ADVANCED BIOFUELS (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3469912-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | Abbott Laboratories (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3091860-B1 | NUTRITIONAL COMPOSITION HAVING LIPOPHILIC COMPOUNDS WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | ABBOTT LAB (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3027632-B1 | RECOVERY OF STEVIOL GLYCOSIDES FROM A FERMENTATION BROTH | DSM IP ASSETS BV (NL) | 2019-03-20 | — | — | EP | disclosed |
| WO-2019051291-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190070227-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | Pendulum Therapeutics, Inc. | 2019-03-07 | — | — | US | disclosed |
| US-20190070228-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | RVRS | 2019-03-07 | — | — | US | disclosed |
| US-20190030096-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | TRINITY CAPITAL INC. | 2019-01-31 | — | — | US | disclosed |
| US-20190029937-A1 | NOREUGENIN GLYCOSIDE DERIVATIVES | UNIVERSITAET HAMBURG (DE) | 2019-01-31 | — | — | US | disclosed |
| US-20190030095-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | TRINITY CAPITAL INC. | 2019-01-31 | — | — | US | disclosed |
| US-10188592-B2 | 2-pyrones | MERCK PATENT GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| EP-3424501-A1 | COMPOSITION USED TO IMPROVE SYMPTOMS OF AUTISM SPECTRUM DISORDER, AND METHOD USING SAME FOR IMPROVING SYMPTOMS OF AUTISM SPECTRUM DISORDER | Tohoku University (JP) | 2019-01-09 | — | — | EP | disclosed |
| CN-109071595-A | Method for reducing trisulfide levels of proteins | 默克专利股份公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-2934190-B1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LAB (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018217651-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
| EP-3402576-A1 | NOREUGENIN GLYCOSIDE DERIVATIVES | Universität Hamburg (DE) | 2018-11-21 | — | — | EP | disclosed |
| WO-2018208647-A1 | TASTE-MODIFIED CREATINE SALTS, COMPOUNDS, COMPOSITIONS AND USES THEREOF | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-10123950-B2 | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180318368-A1 | A METHOD FOR PRODUCING A MEDIUM CONTAINING STEROIDAL GLYCOSIDES FROM PLANT CELLS OF THE GENUS HOODIA | LYKKE RESEARCH LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| EP-2806754-B1 | DITERPENE PRODUCTION | DSM IP ASSETS BV (NL) | 2018-10-24 | — | — | EP | disclosed |
| EP-2649033-B1 | COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS | SYTHEON LTD (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-104812891-B | Cell culture medium | 默克专利有限公司 | 2018-10-12 | — | — | CN | disclosed |
| EP-3373944-A1 | A METHOD FOR PRODUCING A MEDIUM CONTAINING STEROIDAL GLYCOSIDES FROM PLANT CELLS OF THE GENUS HOODIA | Lykke Research Limited (GB) | 2018-09-19 | — | — | EP | disclosed |
| US-20180256582-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BIOMARIN PHARMACEUTICAL INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2018162368-A1 | USE OF COMPATIBLE SOLUTES | MERCK PATENT GMBH (DE) | 2018-09-13 | — | — | WO | disclosed |
| EP-2444082-B1 | Hydroxymethylbutyrate compositions and uses thereof | ABBOTT LAB (US) | 2018-09-12 | — | — | EP | disclosed |
| US-10071037-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-09-11 | — | — | US | disclosed |
| EP-2903458-B1 | METHODS FOR ENHANCING THE EFFECT OF EGCG ON MITIGATING SKELETAL MUSCLE LOSS | ABBOTT LAB (US) | 2018-09-05 | — | — | EP | disclosed |
| US-10058113-B2 | Shelf-stable, clear liquid nutritional compositions comprising epigallocatechin gallate (EGCg) and methods for preparing the same | ABBOTT LABORATORIES (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3362551-A1 | NUTRIENT MEDIUM FOR OSMOTOLERANT MICROORGANISMS | Hochschule Ostwestfalen-Lippe (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-20180221426-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | STOECKER WILLIAM VAN DOVER (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2018145105-A1 | COMPOSITIONS AND METHODS FOR TREATING AND REMOVING SEBORRHEIC KERATOSES | STOECKER MD WILLIAM VAN DOVER (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-3356345-A1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-08 | — | — | EP | disclosed |
| CN-105342994-B | Infusion preparation | 株式会社大塚制药工场 | 2018-08-07 | — | — | CN | disclosed |
| EP-2144590-B1 | SKIN TREATMENT COMPOSITIONS AND METHODS | SYTHEON LTD (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20180207080-A1 | COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018106844-A1 | METHODS AND COMPOSITIONS RELATING TO ISOLATED AND PURIFIED MICROBES | WHOLE BIOME INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9993481-B2 | Methods and compositions for the treatment of metabolic disorders | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2283736-B1 | Infant formulas containing docosahexaenoic acid and lutein | ABBOTT LAB (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3322400-A1 | COMPOSITIONS OF FLUORINATED SURFACTANTS AND ANTIOXIDANTS | Merck Patent GmbH (DE) | 2018-05-23 | — | — | EP | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| CN-107847549-A | Method for increasing the glutathione level in cell | 默克专利股份公司 | 2018-03-27 | — | — | CN | disclosed |
| US-20180077952-A1 | INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN | ABBOTT LABORATORIES (US) | 2018-03-22 | — | — | US | disclosed |
| EP-2664674-B1 | Method for the production of bioproducts | NATURALLY SCIENTIFIC TECH LIMITED (GB) | 2018-03-21 | — | — | EP | disclosed |
| WO-2018039229-A1 | COMPOSITIONS AND METHODS FOR RESTORING EPIDERMAL INTEGRITY AND FUNCTION AND TREATING DERMATOLOGICAL DISEASES | SYTHEON LIMITED (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-3282017-A1 | DICARBOXYLIC ACID FERMENTATION PROCESS | DSM IP Assets B.V. (NL) | 2018-02-14 | — | — | EP | disclosed |
| US-9884149-B2 | Infusion preparation | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2018-02-06 | — | — | US | disclosed |
| US-RE46698-E1 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20180020661-A1 | POWDER FORMULATION CONTAINING INSECT REPELLENT | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-9861120-B2 | Infant formulas containing docosahexaenoic acid and lutein | ABBOTT LABORATORIES (US) | 2018-01-09 | — | — | US | disclosed |
| US-9861575-B2 | Vitamin-containing nutrition infusion for administration through peripheral vein | EA PHARMA CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9844531-B2 | Methods of maintaining and improving muscle function | ABBOTT LABORATORIES (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170333298-A1 | Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | LABORATORY SKIN CARE, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2734210-B1 | GALACTOOLIGOSACCHARIDES FOR PREVENTING INJURY AND/OR PROMOTING HEALING OF THE GASTROINTESTINAL TRACT | ABBOTT LAB (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2470667-B1 | DICARBOXYLIC ACID FERMENTATION PROCESS | DSM IP ASSETS BV (NL) | 2017-11-15 | — | — | EP | disclosed |
| US-20170304530-A1 | INFUSION PREPARATION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170304168-A1 | PHENYL KETONE DERIVATIVES AS SELF-TANNING AGENTS | MERCK PATENT GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3235387-A1 | SHELF-STABLE, CLEAR LIQUID NUTRITIONAL COMPOSITIONS COMPRISING EPIGALLOCATECHIN GALLATE (EGCG) AND METHODS FOR PREPARING THE SAME | Abbott Laboratories (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9790521-B2 | Host cells and methods for production of isobutanol | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170275652-A1 | Host Cells and Methods for Production of Isobutanol | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170258791-A1 | PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND | PROJECT PM CO., LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| EP-2903459-B1 | SHELF-STABLE, CLEAR LIQUID NUTRITIONAL COMPOSITIONS COMPRISING EPIGALLOCATECHIN GALLATE (EGCG) AND PROTEINS | ABBOTT LAB (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9752171-B2 | Pentose fermentation by a recombinant microorganism | CODEXIS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-3210598-A1 | INFUSION PREPARATION | Otsuka Pharmaceutical Factory, Inc. (JP) | 2017-08-30 | — | — | EP | disclosed |
| CN-107106603-A | Orally taken product | 辉瑞大药厂 | 2017-08-29 | — | — | CN | disclosed |
| US-20170238583-A1 | SHELF-STABLE, CLEAR LIQUID NUTRITIONAL COMPOSITIONS COMPRISING EPIGALLOCATECHIN GALATE (EGCG) AND METHODS FOR PREPARING THE SAME | ABBOTT LABORATORIES | 2017-08-24 | — | — | US | disclosed |
| EP-2702989-B1 | STABLE PHARMACEUTICAL COMPOSITION | KOWA CO (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-9700501-B2 | Use of indole compounds as a cosmetic | MERCK PATENT GMBH (DE) | 2017-07-11 | — | — | US | disclosed |
| EP-3187185-A1 | PHARMACEUTICAL COMPOSITION FORMED BY COMBINING PYRIDOXAMINE COMPOUND AND THIAMINE COMPOUND | Project Pm Co. Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9687600-B2 | Infusion preparation | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2017-06-27 | — | — | US | disclosed |
| US-20170165297-A1 | METHODS FOR ENHANCING THE EFFECT OF EGCG ON MITIGATING SKELETAL MUSCLE LOSS | ABBOTT LABORATORIES (US) | 2017-06-15 | — | — | US | disclosed |
| US-9675097-B2 | Shelf-stable, clear liquid nutritional compositions comprising epigallocatechin gallate (EGCG) and methods for preparing the same | ABBOTT LABORATORIES (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170157225-A1 | COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHANOBREVIBACTER RUMINANTIUM | PASTORAL GREENHOUSE GAS RESEARCH LTD (NZ) | 2017-06-08 | — | — | US | disclosed |
| EP-3176265-A1 | DICARBOXYLIC ACID PRODUCTION BY FERMENTATION AT LOW PH | DSM IP Assets B.V. (NL) | 2017-06-07 | — | — | EP | disclosed |
| US-9655828-B2 | Glucuronolactone derivatives as self-tanning substances | MERCK PATENT GMBH (DE) | 2017-05-23 | — | — | US | disclosed |
| WO-2017081489-A1 | A METHOD FOR PRODUCING A MEDIUM CONTAINING STEROIDAL GLYCOSIDES FROM PLANT CELLS OF THE GENUS HOODIA | LYKKE RESEARCH LIMITED (GB) | 2017-05-18 | — | — | WO | disclosed |
| US-9649268-B2 | Glucuronolactone derivatives as self-tanning substances | MERCK PATENT GMBH (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9642784-B2 | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2659889-B1 | ANTIPYRETIC/ANALGESIC COMPOSITION | KOWA CO (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-20170105910-A1 | UV FILTER CAPSULE | BASF SE (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170086481-A1 | NUTRITIONAL COMPOSITIONS COMPRISING A LIPOPHILIC ACTIVE INGREDIENT | ABBOTT LABORATORIES (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170087255-A1 | IN-VIVO INTRAVASCULAR BLOOD REPLACING LIQUID, IN-VIVO INTRAVASCULAR BLOOD REPLACING LIQUID FORMULATION, AND PREFILLED SYRINGE | TERUMO KABUSHIKI KAISHA (JP) | 2017-03-30 | — | — | US | disclosed |
| US-9603784-B2 | Process for treating sol-gel capsules | MERCK PATENT GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20170081339-A1 | COMPOSITIONS AND METHODS FOR RESTORING EPIDERMAL INTEGRITY AND FUNCTION AND TREATING DERMATOLOGICAL DISEASES | SYTHEON LIMITED (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170067083-A1 | PRODUCTION OF BIOFUEL FROM TISSUE CULTURE SOURCES | NATURALLY SCIENT TECH LTD (GB) | 2017-03-09 | — | — | US | disclosed |
| EP-3138566-A1 | TREATMENT OF PHENYLKETONURIA WITH BH4 | BioMarin Pharmaceutical Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9579347-B2 | Methods for enhancing the effect of EGCg on mitigating skeletal muscle loss | ABBOTT LABORATORIES (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2297297-B1 | SUCCINIC ACID PRODUCTION BY FERMENTATION AT LOW PH | DSM IP ASSETS BV (NL) | 2017-02-08 | — | — | EP | disclosed |
| US-9562244-B2 | Method of producing plant suspension cells in a growth medium enriched with carbonic acid | NATURALLY SCIENTIFIC TECHNOLOGIES LIMITED (GB) | 2017-02-07 | — | — | US | disclosed |
| US-20170027996-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | TRINITY CAPITAL INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170020932-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | Pendulum Therapeutics, Inc. | 2017-01-26 | — | — | US | disclosed |
| EP-2152685-B1 | SKIN LIGHTENING COMPOSITIONS AND METHODS | SYTHEON LTD (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-2144608-B1 | SUNSCREEN COMPOSITIONS AND METHODS | SYTHEON LTD (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20170014325-A1 | 2-PYRONES | MERCK PATENT GMBH (DE) | 2017-01-19 | — | — | US | disclosed |
| US-20170014535-A1 | IN-VIVO INTRAVASCULAR BLOOD REPLACING LIQUID, IN-VIVO INTRAVASCULAR BLOOD REPLACING LIQUID FORMULATION, AND PREFILLED SYRINGE | TERUMO KABUSHIKI KAISHA (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20160374971-A1 | DIETARY SUPPLEMENTS FOR TREATING CANCER | THE TRUSTEES OF PRINCETON UNIVERSITY | 2016-12-29 | — | — | US | disclosed |
| US-20160367558-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BIOMARIN PHARM INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160361291-A1 | METHODS FOR INCREASING SKELETAL MUSCLE PROTEIN SYNTHESIS USING GREEN TEA EXTRACT | ABBOTT LABORATORIES (US) | 2016-12-15 | — | — | US | disclosed |
| EP-2576804-B1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2726624-B1 | PROCESS FOR PRODUCING DICARBOXYLIC ACIDS EMPLOYING FUNGAL CELLS | DSM IP ASSETS BV (NL) | 2016-11-30 | — | — | EP | disclosed |
| US-20160339263-A1 | SKIN LIGHTENER IN PHOTOTHERAPY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-9499508-B2 | 2-pyrones | MERCK PATENT GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-3091859-A1 | METHODS FOR INCREASING SKELETAL MUSCLE PROTEIN SYNTHESIS USING GREEN TEA EXTRACT | Abbott Laboratories (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9492364-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9486487-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | WHOLE BIOME INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160309770-A1 | TRANSLUCENT, HIGH ACID, LOW VISCOSITY, HIGH CALORIC DENSITY NUTRITIONAL COMPOSITION | ABBOTT LABORATORIES (US) | 2016-10-27 | — | — | US | disclosed |
| US-9474766-B2 | Use of a reduced calorie infant formula containing nucleotides and/or carotenoids for reducing adverse health effects later in life | ABBOTT LABORATORIES (US) | 2016-10-25 | — | — | US | disclosed |
| US-9458142-B2 | Substituted quinones or analogues as colouring agents | MERCK PATENT GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20160271189-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF SKIN DISORDERS | Pendulum Therapeutics, Inc. | 2016-09-22 | — | — | US | disclosed |
| US-9446184-B2 | Infusion preparation | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447442-B2 | Production of biofuel from tissue culture sources | NATURALLY SCIENTIFIC TECHNOLOGIES LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9441016-B2 | Complete genome sequence of the methanogen Methanobrevibacter ruminantium | PASTORAL GREENHOUSE GAS RESEARCH LTD. (NZ) | 2016-09-13 | — | — | US | disclosed |
| US-20160256479-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2016-09-08 | — | — | US | disclosed |
| US-9433624-B2 | Methods and compositions for the treatment of metabolic disorders | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-09-06 | — | — | US | disclosed |
| EP-2309974-B1 | USE OF 5-(7-METHOXY-3,3-DIMETHYL-2,3-DIHYDRO-1-BENZOXEPIN-5-YL)-3-METHYL-PENTA-2,4-DIENOIC | MERCK PATENT GMBH (DE) | 2016-08-31 | — | — | EP | disclosed |
| US-9422582-B2 | Host cells and methods for production of isobutanol | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422581-B2 | Host cells and methods for production of isobutanol | BUTAMAX ADVANCED BIOFUELS LLC (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160228476-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | TRINITY CAPITAL INC. | 2016-08-11 | — | — | US | disclosed |
| EP-3053582-A1 | VITAMIN-CONTAINING NUTRITION INFUSION FOR ADMINISTRATION THROUGH PERIPHERAL VEIN | Ajinomoto Co., Inc. (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20160219913-A1 | NUTRITIONAL COMPOSITION HAVING LIPOPHILIC COMPOUNDS WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | ABBOTT LABORATORIES (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160213041-A1 | NUTRITIONAL COMPOSITION HAVING LIPOPHILIC COMPOUNDS WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | ABBOTT LABORATORIES (US) | 2016-07-28 | — | — | US | disclosed |
| EP-1708690-B1 | TREATMENT OF PHENYLKETONURIA WITH BH4 | BIOMARIN PHARM INC (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2301529-B1 | HYDROXYMETHYLBUTYRATE COMPOSITIONS AND USES THEREOF | ABBOTT LAB (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160194670-A1 | FERMENTATION PROCESS | Technip Energies France (FR) | 2016-07-07 | — | — | US | disclosed |
| US-9382224-B2 | 7-acyloxychromen-4-one derivatives and the use thereof as self-tanning substances | MERCK PATENT GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| CN-103228791-B | Dicarboxylic acid production technique | 帝斯曼知识产权资产管理有限公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20160160257-A1 | DITERPENE PRODUCTION IN YARROWIA | DSM IP ASSETS B.V. (NL) | 2016-06-09 | — | — | US | disclosed |
| US-9353387-B2 | Dicarboxylic acid production process | DSM IP ASSETS B.V. (NL) | 2016-05-31 | — | — | US | disclosed |
| WO-2016079576-A1 | A PROCESS FOR THE PREPARATION OF A THIAMINE DERIVATIVE AND SALT THEREOF | ASHMI LIFE SCIENCES PRIVATE LIMITED (IN) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079576-A1 | A PROCESS FOR THE PREPARATION OF A THIAMINE DERIVATIVE AND SALT THEREOF | ASHMI LIFE SCIENCES PRIVATE LIMITED (IN) | 2016-05-26 | — | — | WO | disclosed |
| US-20160136192-A1 | METHODS AND COMPOSITIONS FOR ENHANCING COGNITIVE PERFORMANCE | ABBOTT LABORATORIES (US) | 2016-05-19 | — | — | US | disclosed |
| EP-3016531-A2 | DIETARY SUPPLEMENTS AND COMPOSITION FOR TREATING CANCER | The Trustees Of Princeton University (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20160106131-A1 | USE OF HMB TO IMPROVE QUALITY OF LIFE FOR HOSPITALIZED PATIENTS | ABBOTT LABORATORIES (US) | 2016-04-21 | — | — | US | disclosed |
| EP-3007690-A1 | METHODS AND COMPOSITIONS FOR ENHANCING COGNITIVE PERFORMANCE | Abbott Laboratories (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2567700-B1 | VITAMIN-CONTAINING NUTRITION INFUSION FOR ADMINISTRATION THROUGH PERIPHERAL VEIN | AJINOMOTO KK (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20160101231-A1 | INFUSION PREPARATION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9309272-B2 | Metal oxide particles aftertreated with organic phosphorus compounds | MERCK PATENT GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| EP-3002334-A1 | METHOD FOR THE PRODUCTION OF BIOPRODUCTS | Naturally Scientific Technologies Limited (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-2999359-A1 | METHODS FOR ENHANCING AGED MUSCLE REGENERATION | ABBOTT LABORATORIES (US) | 2016-03-30 | — | — | EP | disclosed |
| CN-105407744-A | Low calorie infant formula containing beta-hydroxy-beta-methylbutyric acid | ABBOTT LAB | 2016-03-16 | — | — | CN | disclosed |
| US-9283269-B2 | Method for reducing the allergenicity of animal dander | IMMUNOPATH PROFILE, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20160066610-A1 | METHODS FOR ENHANCING AGED MUSCLE REGENERATION | ABBOTT LABORATORIES (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2016029113-A1 | METHODS OF INCREASING ENDOGENOUS PRODUCTION OF BETA-HYDROXY-BETA-METHYLBUTYRATE | ABBOTT LABORATORIES (US) | 2016-02-25 | — | — | WO | disclosed |
| EP-2986165-A1 | LOW CALORIE INFANT FORMULA CONTAINING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | ABBOTT LABORATORIES (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986158-A1 | METHODS OF MAINTAINING AND IMPROVING MUSCLE FUNCTION | ABBOTT LABORATORIES (US) | 2016-02-24 | — | — | EP | disclosed |
| CN-105357984-A | Low calorie infant formula containing | ABBOTT LAB | 2016-02-24 | — | — | CN | disclosed |
| EP-2984941-A1 | NUTRITIONAL PRODUCTS HAVING IMPROVED ORGANOLEPTIC PROPERTIES | Abbott Laboratories (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20160038457-A1 | METHODS OF MAINTAINING AND IMPROVING MUSCLE FUNCTION | ABBOTT LABORATORIES (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160029683-A1 | LOW CALORIE INFANT FORMULA CONTAINING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | ABBOTT LABORATORIES (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160021921-A1 | PRETERM INFANT NUTRITIONAL COMPOSITIONS CONTAINING BETA-HYDROXY-BETA-METHYLBUTYRIC ACID | ABBOTT LABORATORIES (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160015606-A1 | Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | LABORATORY SKIN CARE, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160010132-A1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-01-14 | — | — | US | disclosed |
| US-20160008253-A1 | GLUCURONOLACTONE DERIVATIVES AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| CN-105247064-A | Extracellular diterpene production | DSM IP ASSETS BV | 2016-01-13 | — | — | CN | disclosed |
| WO-2015187795-A1 | NUTRITIONAL COMPOSITIONS COMPRISING A LIPOPHILIC ACTIVE INGREDIENT | ABBOTT LABORATORIES (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20150342974-A1 | NUTRITIONAL COMPOSITIONS COMPRISING NEUROPROTECTIVE DIETARY OLIGOSACCHARIDES | ABBOTT LABORATORIES (US) | 2015-12-03 | — | — | US | disclosed |
| EP-2306965-B1 | USE OF INDOLE COMPOUNDS AS A COSMETIC | MERCK PATENT GMBH (DE) | 2015-12-02 | — | — | EP | disclosed |
| US-20150320778-A1 | HUMAN MILK OLIGOSACCHARIDES TO AMELIORATE SYMPTOMS OF STRESS | ABBOTT LABORATORIES (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150320712-A1 | Nutritional Composition for Gastrostomy-Tube Patients | AJINOMOTO CO., INC. (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9181161-B2 | Use of dicyclohexylmethanol derivatives having antimicrobial properties | MERCK PATENT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20150315177-A1 | SUBSTITUTED QUINONES OR ANALOGUES AS COLOURING AGENTS | MERCK PATENT GMBH (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150306002-A1 | 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES | MERCK PATENT GMBH (DE) | 2015-10-29 | — | — | US | disclosed |
| EP-2934189-A1 | HUMAN MILK OLIGOSACCHARIDES TO AMELIORATE SYMPTOMS OF STRESS | ABBOTT LABORATORIES (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934190-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-1945045-B1 | INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN | ABBOTT LAB (US) | 2015-10-21 | — | — | EP | disclosed |
| CN-103096736-B | Comprise the nutrient liquid of the substantially transparent of HMB calcium and soluble protein | ABBOTT LABORATORIES (US) | 2015-10-07 | — | — | CN | disclosed |
| US-20150265650-A1 | METHODS FOR ENHANCING THE EFFECT OF EGCG ON MITIGATING SKELETAL MUSCLE LOSS | ABBOTT LABORATORIES (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150265516-A1 | COMPOSITIONS CONTAINING CYCLIC PEPTIDES AND METHODS OF USE | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150250221-A1 | SHELF-STABLE, CLEAR LIQUID NUTRITIONAL COMPOSITIONS COMPRISING EPIGALLOCATECHIN GALLATE (EGCG) AND METHODS FOR PREPARING THE SAME | ABBOTT LABORATORIES (US) | 2015-09-10 | — | — | US | disclosed |
| CN-104853621-A | Nutritional formulations for modulating inflammation using human milk oligosaccharides | ABBOTT LAB | 2015-08-19 | — | — | CN | disclosed |
| EP-2903459-A1 | SHELF-STABLE, CLEAR LIQUID NUTRITIONAL COMPOSITIONS COMPRISING EPIGALLOCATECHIN GALLATE (EGCG) AND METHODS FOR PREPARING THE SAME | ABBOTT LABORATORIES (US) | 2015-08-12 | — | — | EP | disclosed |
| US-9095510-B2 | Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| CN-104812891-A | Cell culture medium | MERCK PATENT GMBH | 2015-07-29 | — | — | CN | disclosed |
| CN-104789506-A | Thalassospira sp. capable of degrading polycyclic aromatic hydrocarbons under saline environment and application thereof | UNIV TSINGHUA | 2015-07-22 | — | — | CN | disclosed |
| WO-2015105981-A2 | CONDITIONAL ESSENTIALITY OF HMB | ABBOTT LABORATORIES (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150182432-A1 | PHENYL KETONE DERIVATIVES AS SELF-TANNING AGENTS | MERCK PATENT GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| WO-2015095725-A1 | METHODS AND COMPOSITIONS FOR ATTENUATING MUSCLE PROTEIN DEGRADATION AND PRESERVING LEAN BODY MASS | ABBOTT LABORATORIES (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094772-A1 | METHODS FOR INCREASING SKELETAL MUSCLE PROTEIN SYNTHESIS USING GREEN TEA EXTRACT | ABBOTT LABORATORIES (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015094767-A1 | METHODS FOR MAINTAINING OR INCREASING BODYWEIGHT USING DECAFFEINATED GREEN TEA EXTRACT | ABBOTT LABORATORIES (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2884970-A1 | METHODS AND COMPOSITIONS USEFUL FOR IMPROVING BONE AND JOINT HEALTH | ABBOTT LABORATORIES (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20150164824-A1 | METHODS AND COMPOSITIONS USEFUL FOR IMPROVING BONE AND JOINT HEALTH | ABBOTT LABORATORIES (US) | 2015-06-18 | — | — | US | disclosed |
| US-9045745-B2 | Pentose fermentation by a recombinant microorganism | CODEXIS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9044409-B2 | Use of chromen-4-one derivatives | MERCK PATENT GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20150139922-A1 | EXTRACTS OF DARLINGTONIA CALIFORNICA | MERCK PATENT GMBH (DE) | 2015-05-21 | — | — | US | disclosed |
| US-9023889-B2 | Use of ascorbic acid derivatives for the functionalization of matrices | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20150119339-A1 | USE OF HMB TO IMPROVE HEALTH OUTCOMES FOR HOSPITALIZED PATIENTS | ABBOTT LABORATORIES (US) | 2015-04-30 | — | — | US | disclosed |
| US-20150118165-A1 | USE OF CYCLOHEXANOL ETHERS HAVING ANTIMICROBIAL PROPERTIES | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150118172-A1 | USE OF DICYCLOHEXYLMETHANOL DERIVATIVES HAVING ANTIMICROBIAL PROPERTIES | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150098914-A1 | GLUCURONOLACTONE DERIVATIVES AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150072007-A1 | THERAPEUTIC STEM CELL COMPOSITION AND STIMULANT, FACILITATOR, ACCELERATOR, AND SYNERGIZER THEREOF, GROWTH FACTOR, ANTI-INFLAMMATORY COMPOSITION AND USES THEREOF | IMMUNOPATH PROFILE, INC. | 2015-03-12 | — | — | US | disclosed |
| EP-2442676-B1 | SUBSTANTIALLY CLEAR NUTRITIONAL LIQUIDS COMPRISING CALCIUM HMB AND SOLUBLE PROTEIN | ABBOTT LAB (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150057346-A1 | METHODS OF MAINTAINING INTRAMUSCULAR MYOGLOBIN LEVELS, MAINTAINING MAXIMAL AEROBIC CAPACITY, AND ENHANCING THE OXIDATIVE CAPACITY OF MUSCLE IN A SUBJECT | ABBOTT LABORATORIES (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057425-A1 | PROCESS FOR THE CRYSTALLIZATION OF SUCCINIC ACID | ROQUETTE FRERES SA (FR) | 2015-02-26 | — | — | US | disclosed |
| US-20150051295-A1 | USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150031868-A1 | DITERPENE PRODUCTION | DSM IP ASSETS B.V. (NL) | 2015-01-29 | — | — | US | disclosed |
| US-20150024112-A1 | INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN | ABBOTT LABORATORIES (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150010602-A1 | METAL OXIDE PARTICLES AFTERTREATED WITH ORGANIC PHOSPHORUS COMPOUNDS | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011498-A1 | USE OF A REDUCED CALORIE INFANT FORMULA CONTAINING NUCLEOTIDES AND/OR CAROTENOIDS FOR REDUCING ADVERSE HEALTH EFFECTS LATER IN LIFE | ABBOTT LABORATORIES (US) | 2015-01-08 | — | — | US | disclosed |
| WO-2015003021-A2 | DIETARY SUPPLEMENTS AND COMPOSITION FOR TREATING CANCER | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-01-08 | — | — | WO | disclosed |
| US-8916361-B2 | Elongase gene and uses thereof | ABBOTT LABORATORIES (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2014200961-A1 | METHODS AND COMPOSITIONS FOR ENHANCING COGNITIVE PERFORMANCE | ABBOTT LABORATORIES (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8907110-B2 | Benzodioxepin-3-one compounds as dyes or as fluorescent emitters | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906351-B2 | 2,2′-furoin derivatives and use thereof to light skin | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| WO-2014186369-A1 | NUTRITIONAL COMPOSITION COMPRISING ANTHOCYANIDIN(S) AND RELATED METHODS | ABBOTT LABORATORIES (US) | 2014-11-20 | — | — | WO | disclosed |
| US-20140335065-A1 | HUMAN MILK OLIGOSACCHARIDES FOR PREVENTING INJURY AND/OR PROMOTING HEALING OF THE GASTROINTESTINAL TRACT | ABBOTT LABORATORIES (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8883215-B2 | Metal oxide particles aftertreated with organic phosphorus compounds | MERCK PATENT GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| WO-2014179526-A1 | METHODS FOR ENHANCING AGED MUSCLE REGENERATION | ABBOTT LABORATORIES (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-2798070-A1 | PROCESS FOR CELL-FREE PRODUCTION OF CHEMICALS | Süd-Chemie IP GmbH & Co. KG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-20140323950-A1 | SKIN LIGHTENER IN PHOTOTHERAPY | MERCK PATENT GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140308393-A1 | REDUCED CALORIE INFANT FORMULAS CONTAINING SPECIFIC WHEY TO CASEIN RATIOS | ABBOTT LABORATORIES (US) | 2014-10-16 | — | — | US | disclosed |
| US-8859247-B2 | Process for cell-free production of chemicals | SÜD-CHEMIE IP GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859021-B2 | Skin appearance through gene manipulation | Sytheon (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140294789-A1 | GALACTOOLIGOSACCHARIDES FOR PREVENTING INJURY AND/OR PROMOTING HEALING OF THE GASTROINTESTINAL TRACT | ABBOTT LABORATORIES (US) | 2014-10-02 | — | — | US | disclosed |
| US-8846089-B2 | Sugar-coated preparation and production method for the same | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-30 | — | — | US | disclosed |
| WO-2014152616-A1 | LOW CALORIE INFANT FORMULA CONTAINING | ABBOTT LABORATORIES (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140287458-A1 | PHOTOSYNTHETIC PROCESS | NATURALLY SCIENTIFIC TECHNOLOGIES LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| WO-2014144458-A1 | METHODS OF MAINTAINING AND IMPROVING MUSCLE FUNCTION | ABBOTT LABORATORIES (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140242674-A1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140234238-A1 | BENZODIOXEPIN-3-ONE COMPOUNDS AS DYES OR AS FLUORESCENT EMITTERS | MERCK PATENT GMBH (DE) | 2014-08-21 | — | — | US | disclosed |
| EP-2224927-B1 | PTERIN ANALOG FOR TREATING BH4 RESPONSIVE CONDITION | BIOMARIN PHARM INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8785496-B2 | Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting | ABBOTT LABORATORIES (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785495-B2 | Compositions including beta-hydroxy-beta-methylbutyrate | ABBOTT LABORATORIES (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140199726-A1 | PRODUCTION OF BIOFUEL FROM TISSUE CULTURE SOURCES | NATURALLY SCIENTIFIC TECHNOLOGIES LIMITED (GB) | 2014-07-17 | — | — | US | disclosed |
| US-8778993-B2 | Method of using β-hydroxy-β-methylbutyrate for the treatment of disease conditions | ABBOTT LABORATORIES (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778632-B2 | Δ6-desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778994-B2 | Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting | ABBOTT LABORATORIES (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778652-B2 | Pentose fermentation by a recombinant microorganism | CODEXIS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8765103-B2 | Pearlescent pigments containing cosmetic compositions | GLASSFLAKE LIMITED (GB) | 2014-07-01 | — | — | US | disclosed |
| WO-2014100696-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100022-A1 | DIETARY OLIGOSACCHARIDES TO ENHANCE LEARNING AND MEMORY | ABBOTT LABORATORIES (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014099904-A1 | METHODS FOR ENHANCING MOTOR FUNCTION, ENHANCING FUNCTIONAL STATUS AND MITIGATING MUSCLE WEAKNESS IN A SUBJECT | ABBOTT LABORATORIES (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100191-A1 | NUTRITIONAL COMPOSITIONS COMPRISING NEUROPROTECTIVE DIETARY OLIGOSACCHARIDES | ABBOTT LABORATORIES (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100126-A1 | HUMAN MILK OLIGOSACCHARIDES TO AMELIORATE SYMPTOMS OF STRESS | ABBOTT LABORATORIES (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100225-A1 | NUTRITIONAL USE OF HUMAN MILK OLIGOSACCHARIDES | ABBOTT LABORATORIES (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2745705-A1 | Nutritional use of human milk oligosaccharides | Abbott Laboratories (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2745708-A1 | Antidepressant effect of ß-hydroxy-ß-methylbutyrate | Abbott Laboratories, Inc. (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8758501-B2 | Nanoparticulate UV protectant with silicon dioxide coating | MERCK PATENT GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| CN-103874687-A | Benzodioxepin-3-one compounds as dyes or as fluorescent emitters | MERCK PATENT GMBH | 2014-06-18 | — | — | CN | disclosed |
| US-8753684-B2 | Particulate UV protection agent | MERCK PATENT GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8722384-B2 | Methods and compositions for synthesis of long chain polyunsaturated fatty acids | CALGENE LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-8709104-B2 | Dye-ascorbic acid derivatives | MERCK PATENT GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8703173-B2 | Newborn infant formulas and feeding methods | UNIVERSITY COLLEGE LONDON (GB) | 2014-04-22 | — | — | US | disclosed |
| US-8697115-B2 | Method of improving antioxidant status of an infant | ABBOTT LABORATORIES (US) | 2014-04-15 | — | — | US | disclosed |
| WO-2014055830-A1 | SHELF-STABLE, CLEAR LIQUID NUTRITIONAL COMPOSITIONS COMPRISING EPIGALLOCATECHIN GALLATE (EGCG) AND METHODS FOR PREPARING THE SAME | ABBOTT LABORATORIES (US) | 2014-04-10 | — | — | WO | disclosed |
| US-20140099274-A1 | EXTRACTS OF DARLINGTONIA CALIFORNICA | MERCK PATENT GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| EP-2358869-B1 | DELTA-8 DESATURASE GENES, ENZYMES ENCODED THEREBY AND USES THEREOF | ABBOTT LAB (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2710135-A2 | PHOTOSYNTHETIC PROCESS | Naturally Scientific Technologies Limited (GB) | 2014-03-26 | — | — | EP | disclosed |
| CN-103622035-A | A multivitamin/mineral formulation to combat the effects of environmental stress | WYETH LLC | 2014-03-12 | — | — | CN | disclosed |
| EP-2702989-A1 | STABLE PHARMACEUTICAL COMPOSITION | Kowa Company, Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| CN-102239254-B | Delta-8 desaturase genes, enzymes encoded thereby and uses thereof | ABBOTT LAB | 2014-02-26 | — | — | CN | disclosed |
| WO-2014028621-A1 | METHODS AND COMPOSITIONS USEFUL FOR IMPROVING BONE AND JOINT HEALTH | ABBOTT LABORATORIES (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20140030782-A1 | HOST CELLS AND METHODS FOR PRODUCTION OF ISOBUTANOL | BUTAMAX(TM) ADVANCED BIOFUELS LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030783-A1 | HOST CELLS AND METHODS FOR PRODUCTION OF ISOBUTANOL | BUTAMAX(TM) ADVANCED BIOFUELS LLC (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2689014-A2 | HOST CELLS AND METHODS FOR PRODUCTION OF ISOBUTANOL | Butamax (TM) Advanced Biofuels LLC (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20140017765-A1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017187-A1 | Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid as a cosmetic | MERCK PATENT GMBH (DE) | 2014-01-16 | — | — | US | disclosed |
| US-8617528-B2 | Compositions and methods for stabilizing ingredients using 2,4-pentanedione compounds | SYTHEON LTD. (US) | 2013-12-31 | — | — | US | disclosed |
| US-8613910-B2 | Flavonoids as synergists for enhancing the action of self-tanning substances | MERCK PATENT GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| WO-2013188258-A1 | USE OF HMB TO IMPROVE HEALTH OUTCOMES FOR HOSPITALIZED PATIENTS | ABBOTT LABORATORIES (US) | 2013-12-19 | — | — | WO | disclosed |
| US-8609725-B2 | Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate | ABBOTT LABORATORIES (US) | 2013-12-17 | — | — | US | disclosed |
| US-8598228-B2 | Cinnamic acid ascorbates | MERCK PATENT GMBH (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20130313261-A1 | INFUSION PREPARATION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2013-11-28 | — | — | US | disclosed |
| CN-103415498-A | Benzylidene substituted 2,4-pentanedione compounds and use thereof as stabilizers | SYTHEON LTD | 2013-11-27 | — | — | CN | disclosed |
| US-20130309184-A1 | 1,3-DIOXAN-5-ONE COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-20130309305-A1 | Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | LABORATORY SKIN CARE, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2664674-A2 | Method for the production of bioproducts | Naturally Scientific Technologies Limited (GB) | 2013-11-20 | — | — | EP | disclosed |
| CN-103402963-A | Compositions and methods for stabilizing ingredients using 2, 4-pentanedione compounds | SYTHEON LTD | 2013-11-20 | — | — | CN | disclosed |
| EP-2659889-A1 | ANTIPYRETIC/ANALGESIC COMPOSITION | Kowa Co., Ltd. (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-2325300-B1 | Desaturase genes and uses thereof | ABBOTT LAB (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130287716-A1 | 7-ACYLOXYCHROMEN-4-ONE DERIVATIVES AND THE USE THEREOF AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130272978-A1 | DIHYDROXYACETONE MONOETHERS | MERCK PATENT GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| EP-2649034-A2 | BENZYLIDENE SUBSTITUTED 2,4-PENTANEDIONE COMPOUNDS AND USE THEREOF AS STABILIZERS | Sytheon Ltd. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2649033-A2 | COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS | Sytheon Ltd. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130266526-A1 | DIHYDROXYFUMARIC ACID DERIVATIVES AND THE USE THEREOF FOR SKIN LIGHTENING | MERCK PATENT GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| EP-2333052-B1 | Desaturase genes and uses thereof | ABBOTT LAB (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2647370-A1 | TRANSFUSION PREPARATION | Otsuka Pharmaceutical Factory, Inc. (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130261175-A1 | 2-PYRONES | MERCK PATENT GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130243904-A1 | NUTRITIONAL PRODUCTS HAVING IMPROVED ORGANOLEPTIC PROPERTIES | ABBOTT LABORATORIES (US) | 2013-09-19 | — | — | US | disclosed |
| US-8529967-B2 | Sunscreen compositions and methods | SYTHEON LTD. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130217612-A1 | COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHANOBREVIBACTER RUMINANTIUM | ALTERMANN ERIC HEINZ (NZ) | 2013-08-22 | — | — | US | disclosed |
| EP-2622026-A1 | A PROCESS FOR TREATING SOL-GEL CAPSULES | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| CN-103228791-A | Dicarboxylic acid production process | DSM IP ASSETS BV | 2013-07-31 | — | — | CN | disclosed |
| US-8496917-B2 | Compositions and methods for improving skin appearance | SYTHEON LTD (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130183257-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN APPEARANCE | SYTHEON LTD. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130171704-A1 | DICARBOXYLIC ACID PRODUCTION PROCESS | ROQUETTE FRERES SA (FR) | 2013-07-04 | — | — | US | disclosed |
| EP-2608681-A1 | NUTRITIONAL PRODUCTS HAVING IMPROVED ORGANOLEPTIC PROPERTIES | Abbott Laboratories (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130164230-A1 | 2,2'-FUROIN DERIVATIVES AND USE THEREOF TO LIGHT SKIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-27 | — | — | US | disclosed |
| EP-2281053-B1 | Production of biofuel from plant tissue culture sources | NATURALLY SCIENT TECHNOLOGIES LTD (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20130156834-A1 | PROCESS FOR TREATING SOL-GEL CAPSULES | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130125317-A1 | DYE-ASCORBIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130115178-A1 | TANNING ENHANCERS AND SELF-TANNING SUBSTANCES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-09 | — | — | US | disclosed |
| CN-103096736-A | Substantially clear nutritional liquids comprising calcium HMB and soluble protein | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| US-20130108565-A1 | TANNING ENHANCERS AND SELF-TANNING SUBSTANCES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-02 | — | — | US | disclosed |
| US-8426175-B2 | Method for the production of a fermentation product from a pretreated lignocellulosic feedstock | IOGEN ENERGY CORPORATION (CA) | 2013-04-23 | — | — | US | disclosed |
| WO-2013056048-A2 | NUTRITIONAL PRODUCTS COMPRISING BETA-ALANINE | ABBOTT LABORATORIES (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2576804-A1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | Codexis, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2311970-B1 | Method for the production of bioproducts | NATURALLY SCIENT TECHNOLOGIES LTD (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-8414870-B2 | Benzylidene substituted 2,4-pentanedione compounds and use thereof as stabilizers | Sytheon, Ltd. (US) | 2013-04-09 | — | — | US | disclosed |
| CN-101686925-B | Use of ascorbic acid derivatives for the functionalization of matrices | MERCK PATENT GMBH | 2013-04-03 | — | — | CN | disclosed |
| US-20130078228-A1 | VITAMIN-CONTAINING NUTRITION INFUSION FOR ADMINISTRATION THROUGH PERIPHERAL VEIN | AJINOMOTO CO., INC. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20130071898-A1 | HOST CELLS AND METHODS FOR PRODUCTION OF ISOBUTANOL | BUTAMAX(TM) ADVANCED BIOFUELS LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130071904-A1 | ACETATE-RESISTANT YEAST STRAIN FOR THE PRODUCTION OF A FERMENTATION PRODUCT | CODEXIS, INC. | 2013-03-21 | — | — | US | disclosed |
| EP-2567700-A1 | VITAMIN-CONTAINING NUTRITION INFUSION FOR ADMINISTRATION THROUGH PERIPHERAL VEIN | Ajinomoto Co., Inc. (JP) | 2013-03-13 | — | — | EP | disclosed |
| EP-2204453-B1 | Process for cell-free production of chemicals | SUED CHEMIE IP GMBH & CO KG (DE) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059924-A1 | PHOTOSTABILISERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130058879-A1 | TRIAZINES AS REACTION ACCELERATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130045174-A1 | USE OF INDOLE COMPOUNDS AS A COSMETIC | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130011350-A1 | METAL OXIDE PARTICLES AFTERTREATED WITH ORGANIC PHOSPHORUS COMPOUNDS | SACHTLEBEN CHEMIE GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-20130011498-A1 | METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR REDUCING TUMOR GROWTH RATE | ABBOTT LABORATORIES (US) | 2013-01-10 | — | — | US | disclosed |
| CN-102869362-A | Vitamin-mixed nutrient infusion for peripheral intravenous administration | AJINOMOTO KK | 2013-01-09 | — | — | CN | disclosed |
| WO-2013003219-A1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS, INC. (US) | 2013-01-03 | — | — | WO | disclosed |
| US-20130004998-A1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| EP-1598422-B1 | Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants | CALGENE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2533753-A2 | SUNSCREEN COMPOSITIONS COMPRISING UNIFORM, RIGID, SPHERICAL, NANOPOROUS CALCIUM PHOSPHATE PARTICLES, AND METHODS OF MAKING AND USING THE SAME | Laboratory Skin Care, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120308656-A1 | SUGAR-COATED PREPARATION AND PRODUCTION METHOD FOR THE SAME | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8324210-B2 | Pterin analogs | BIOMARIN PHARMACEUTICAL, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2012160360-A2 | PHOTOSYNTHETIC PROCESS | NATURALLY SCIENTIFIC TECHNOLOGIES LIMITED (GB) | 2012-11-29 | — | — | WO | disclosed |
| US-8293784-B2 | α-amino acid derivatives for improving solubility | MERCK PATENT GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| CN-102740854-A | Loxoprofen-containing pharmaceutical composition | KOWA CO | 2012-10-17 | — | — | CN | disclosed |
| US-20120258873-A1 | REDUCTION OF 2,3-DIHYDROXY-2-METHYL BUTYRATE (DHMB) IN BUTANOL PRODUCTION | BUTAMAX(TM) ADVANCED BIOFUELS LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258154-A1 | PARTICULATE UV PROTECTION AGENT | SACHTLEBEN CHEMIE GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120252085-A1 | METHOD FOR THE PRODUCTION OF A FERMENTATION PRODUCT FROM A PRETREATED LIGNOCELLULOSIC FEEDSTOCK | IOGEN ENERGY CORPORATION (CA) | 2012-10-04 | — | — | US | disclosed |
| CN-102711517-A | Soy protein-based nutritional formula with good stability | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| WO-2012129555-A2 | HOST CELLS AND METHODS FOR PRODUCTION OF ISOBUTANOL | BUTAMAX (TM) ADVANCED BIOFUELS LLC (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120238722-A1 | PROCESS FOR THE CRYSTALLIZATION OF SUCCINIC ACID | ROQUETTE FRERES SA (FR) | 2012-09-20 | — | — | US | disclosed |
| EP-2498772-A2 | COMPOSITION AND METHODS FOR IMPROVING SKIN APPEARANCE | Sytheon Ltd. (US) | 2012-09-19 | — | — | EP | disclosed |
| US-8268293-B2 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8263147-B2 | Infant formulas containing docosahexaenoic acid and lutein | ABBOTT LABORATORIES (US) | 2012-09-11 | — | — | US | disclosed |
| CN-101744645-B | Nanometer biological robot and application thereof | INST BIOPHYSICS CN ACAD SCI | 2012-09-05 | — | — | CN | disclosed |
| CN-101163659-B | Antioxidants | MERCK PATENT GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8247653-B2 | Delta-8 desaturase genes, enzymes encoded thereby and uses thereof | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120196829-A1 | METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR THE PREVENTION AND TREATMENT OF DISEASE CONDITIONS | ABBOTT LABORATORIES (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120189714-A1 | COMPOSITIONS INCLUDING BETA-HYDROXY-BETA-METHYLBUTYRATE | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189717-A1 | METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE AND FATTY ACIDS FOR TREATING DISEASE-ASSOCIATED WASTING | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189715-A1 | COMPOSITIONS INCLUDING BETA-HYDROXY-BETA-METHYLBUTYRATE AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189716-A1 | METHOD OF USING BETA-HYDROXY-BETA-METHYLBUTYRATE FOR TREATING DISEASE-ASSOCIATED WASTING | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120177752-A1 | NUTRITIONAL COMPOSITIONS INCLUDING BETA-HYDROXY-BETA-METHYLBUTYRATE | ABBOTT LABORATORIES (US) | 2012-07-12 | — | — | US | disclosed |
| US-8217077-B2 | HMB uses thereof | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2470660-A1 | COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHANOBREVIBACTER RUMINANTIUM | Pastoral Greenhouse Gas Research Ltd (NZ) | 2012-07-04 | — | — | EP | disclosed |
| EP-2470174-A1 | USE OF FAA AND ITS DERIVATIVES IN COSMETICS AND DERMATOLOGY | Merck Patent GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| WO-2012078546-A2 | COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS | SYTHEON LTD. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078544-A2 | BENZYLIDENE SUBSTITUTED 2,4-PENTANEDIONE COMPOUNDS AND USE THEREOF AS STABILIZERS | SYTHEON LTD. (US) | 2012-06-14 | — | — | WO | disclosed |
| CN-101528758-B | [(4-oxo-4h-chromen-3-yl)-hydroxy methyl]- or [(4-oxo-4h-chromen-3-yl)-methyl]-phosphonic acid derivates | MERCK PATENT GMBH | 2012-06-13 | — | — | CN | disclosed |
| US-20120141394-A1 | BENZYLIDENE SUBSTITUTED 2,4-PENTANEDIONE COMPOUNDS AND USE THEREOF AS STABILIZERS | SYTHEON LIMITED (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141395-A1 | COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS | SYTHEON LIMITED (US) | 2012-06-07 | — | — | US | disclosed |
| US-8192968-B2 | Method for the production of a fermentation product from a pretreated lignocellulosic feedstock | IOGEN ENERGY CORPORATION (CA) | 2012-06-05 | — | — | US | disclosed |
| EP-1480993-B2 | DESATURASE GENES, ENZYMES ENCODED THEREBY, AND USES THEREOF | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | disclosed |
| CN-1906204-B | Flavonoid complexes comprising cyclodextrins | MERCK PATENT GMBH | 2012-05-09 | — | — | CN | disclosed |
| US-20120108599-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2444082-A2 | Hydroxymethylbutyrate compositions and uses thereof | Abbott Laboratories (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2012041438-A1 | A PROCESS FOR TREATING SOL-GEL CAPSULES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-8143486-B2 | Delta-5 desaturase and uses thereof | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143383-B2 | Δ-6 desaturase and uses thereof | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120052028-A1 | CINNAMIC ACID ASCORBATES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012027287-A1 | NUTRITIONAL PRODUCTS INCLUDING PEA PROTEIN HYDROLYSATES | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027285-A1 | NUTRITIONAL PRODUCTS HAVING IMPROVED ORGANOLEPTIC PROPERTIES | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012024046-A2 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120039827-A1 | Sunscreen compositions and methods | SYTHEON LIMITED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040422-A1 | DICARBOXYLIC ACID PRODUCTION PROCESS | DSM IP ASSET B.V. (NL) | 2012-02-16 | — | — | US | disclosed |
| US-8106233-B2 | Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing | MERCK PATENT GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022072-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012009272-A2 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20110294170-A1 | Pentose Fermentation By a Recombinant Microorganism | CODEXIS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011150313-A1 | PENTOSE FERMENTATION BY A RECOMBINANT MICROORGANISM | CODEXIS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011150318-A1 | ACETATE-RESISTANT YEAST STRAIN FOR THE PRODUCTION OF A FERMENTATION PRODUCT | CODEXIS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2389177-A1 | A MULTIVITAMIN/MINERAL FORMULATION TO COMBAT THE EFFECTS OF ENVIRONMENTAL STRESS; IMPROVE IMMUNITY AND IMPROVE ENERGY WHILE ADDRESSING VITAMIN AND MINERAL DEFICIENCIES WITHOUT THE NEGATIVE SIDE EFFECTS OF A MEGA DOSE NUTRITIONAL SUPPLEMENT | Wyeth LLC (US) | 2011-11-30 | — | — | EP | disclosed |
| EP-1392823-B1 | DESATURASE GENES AND USES THEREOF | ABBOTT LAB (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8067416-B2 | Methods and compositions for the treatment of metabolic disorders | MERCK EPROVA AG (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8067674-B2 | Desaturase genes, enzymes encoded thereby, and uses thereof | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110280943-A1 | Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | LABORATORY SKIN CARE, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110274791-A1 | MULTIVITAMIN/MINERAL FORMULATION TO COMBAT THE EFFECTS OF ENVIRONMENTAL STRESS; IMPROVED IMMUNITY AND IMPROVE ENERGY WHILE ADDRESSING VITAMIN AND MINERAL DEFICIENCIES WITHOUT THE NEGATIVE SIDE EFFECTS OF A MEGA DOSE NUTRITIONAL SUPPLEMENT | WYETH LLC | 2011-11-10 | — | — | US | disclosed |
| CN-102239254-A | Delta-8 desaturase genes, enzymes encoded thereby and uses thereof | ABBOTT LABORATIRES | 2011-11-09 | — | — | CN | disclosed |
| US-8052963-B2 | [(4-oxo-4H-chromen-3-yl)hydroxymethyl]- or [(4-oxo-4H-chromen-3-yl)methyl]phosphonic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-08 | — | — | US | disclosed |
| US-20110262585-A1 | NEWBORN INFANT FORMULAS AND FEEDING METHODS | UNIVERSITY COLLEGE LONDON (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110256260-A2 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATD FATTY ACIDS | CALGENE LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-8039033-B2 | Method and device for preparing coffee | Coffee Innovation Group B.V. (NL) | 2011-10-18 | — | — | US | disclosed |
| US-20110213039-A1 | INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN | ABBOTT LABORATORIES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| EP-2358869-A1 | DELTA-8 DESATURASE GENES, ENZYMES ENCODED THEREBY AND USES THEREOF | Abbott Laboratories (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7998501-B2 | Comprises from 0.5 to 1.00 grams of protein and 25 to 50 kilocalories per 100 ml of formula; aids in reducing the occurrence or extent of insulin resistance or atherosclerosis or coronary artery disease in an individual later in life | UNIVERSITY COLLEGE LONDON (GB) | 2011-08-16 | — | — | US | disclosed |
| EP-1952843-B1 | Photostable organic sunscreen compounds with antioxidant properties and compositions obtained therefrom | MERCK PATENT GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7968692-B2 | Nutrients, animal feeds, cosmetics; elongation of polyunsaturated fatty acid | ABBOTT LABORATORIES (US) | 2011-06-28 | — | — | US | disclosed |
| US-20110152292-A1 | SALTS COMPRISING A PYRIMIDINECARBOXYLIC ACID DERIVATIVE FOR COSMETIC USE | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110144130-A1 | Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid as a cosmetic | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110142777-A1 | Use of indole compounds as a cosmetic | MERCK PATENT GESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| EP-2333052-A1 | Desaturase genes and uses thereof | Abbott Laboratories (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7960430-B2 | Flavonoid complexes with cyclodextrins | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20110129573-A1 | Soy Protein-Based Nutritional Formula with Superior Stability | ABBOTT LABORATORIES | 2011-06-02 | — | — | US | disclosed |
| EP-2325300-A1 | Desaturase genes and uses thereof | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011059866-A2 | COMPOSITION AND METHODS FOR IMPROVING SKIN APPEARANCE | SYTHEON LTD. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110117036-A1 | Compositions and Methods for Improving Skin Appearance | SYTHEON LIMITED (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011060099-A2 | SUNSCREEN COMPOSITIONS COMPRISING UNIFORM, RIGID, SPHERICAL, NANOPOROUS CALCIUM PHOSPHATE PARTICLES, AND METHODS OF MAKING AND USING THE SAME | LABORATORY SKIN CARE, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-7943662-B2 | For skin/hair light protection; cosmetics | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-05-17 | — | — | US | disclosed |
| EP-1871182-B1 | CONCENTRATED LIQUID HUMAN MILK FORTIFIER (HMF) | ABBOTT LAB (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311970-A1 | Method for the production of bioproducts | Naturally Scientific Technologies Limited (GB) | 2011-04-20 | — | — | EP | disclosed |
| EP-2309974-A2 | USE OF 5-(7-METHOXY-3,3-DIMETHYL-2,3-DIHYDRO-1-BENZOXEPIN-5-YL)-3-METHYL-PENTA-2,4-DIENOIC | Merck Patent GmbH (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2306965-A1 | USE OF INDOLE COMPOUNDS AS A COSMETIC | Merck Patent GmbH (DE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2301529-A1 | Hydroxymethylbutyrate compositions and uses thereof | Abbott Laboratories (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7906684-B2 | Antioxidants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-15 | — | — | US | disclosed |
| EP-1656039-B2 | CALCIUM FORTIFIED SOY BASED INFANT NUTRITIONAL FORMULAS | ABBOTT LAB (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2011023287-A1 | USE OF FAA AND ITS DERIVATIVES IN COSMETICS AND DERMATOLOGY | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025394-A1 | COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHANOBREVIBACTER RUMINANTIUM | PASTORAL GREENHOUSE GAS RESEARCH LTD (NZ) | 2011-03-03 | — | — | WO | disclosed |
| US-20110054027-A1 | PRODUCTION OF BIOFUEL FROM TISSUE CULTURE SOURCES | NATURALLY SCIENTIFIC TECHNOLOGIES LIMITED (UK) | 2011-03-03 | — | — | US | disclosed |
| US-20110039924-A1 | ALPHA-AMINO ACID DERIVATIVES FOR IMPROVING SOLUBILITY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2283736-A1 | Infant formulas containing docosahexaenoic acid and lutein | Abbott Laboratories (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2281053-A2 | PRODUCTION OF BIOFUEL FROM PLANT TISSUE CULTURE SOURCES | Naturally Scientific Technologies Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-20110027209-A1 | Compositions Containing Cyclic Peptides And Methods Of Use | MERCK PATENT GESELLSCHAFT (DE) | 2011-02-03 | — | — | US | disclosed |
| US-7867993-B2 | Preparation containing oxidized flavonoid derivatives | MERCK PATENT GMBH (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20110003360-A1 | DELTA-6 DESATURASE AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003351-A1 | DELTA-5 DESATURASE AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-01-06 | — | — | US | disclosed |
| US-7863478-B2 | 1,3-Bis-[3-(4-methoxyphenyl)-2-propenoyloxy]-2-oxopropane; novel alpha-hydroxyketone derivatives as light-protection filters for cosmetic or drug products; used in cosmetic protective coatings; solar radiation; sunscreen agents; aging resistance; wrinkle resistance; food additives; dermatology | MERCK PATENT GMBH (DE) | 2011-01-04 | — | — | US | disclosed |
| US-20100322880-A1 | UVA FILTERS BASED ON ASCORBIC ACID DERIVATIVES | MERCK PATENT GMBH | 2010-12-23 | — | — | US | disclosed |
| US-20100322881-A1 | UVB FILTER BASED ON ASCORBIC ACID DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-12-23 | — | — | US | disclosed |
| EP-2259768-A1 | COMPOSITIONS CONTAINING CYCLIC PEPTIDES AND METHODS OF USE | Merck Patent GmbH (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100310710-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | MONSANTO TECHNOLOGY LLC (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100291009-A1 | PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-7829126-B2 | Infant formulas containing docosahexaenoic acid and lutein | ABBOTT LABORATORIES (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2224927-A1 | PTERIN ANALOG FOR TREATING BH4 RESPONSIVE CONDITION | BioMarin Pharmaceutical Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-7785774-B2 | Adjustable molecular motor micropower biosensor and its application | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2010-08-31 | — | — | US | disclosed |
| US-20100215594-A1 | Tyrosinase Inhibitors | MERCK PATENT GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100209463-A1 | UV FILTER CAPSULE | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-1747773-B1 | Photostable organic sunscreen compositions with antioxidant properties | MERCK PATENT GMBH (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010085530-A1 | A MULTIVITAMIN/MINERAL FORMULATION TO COMBAT THE EFFECTS OF ENVIRONMENTAL STRESS; IMPROVE IMMUNITY AND IMPROVE ENERGY WHILE ADDRESSING VITAMIN AND MINERAL DEFICIENCIES WITHOUT THE NEGATIVE SIDE EFFECTS OF A MEGA DOSE NUTRITIONAL SUPPLEMENT | WYETH LLC (US) | 2010-07-29 | — | — | WO | disclosed |
| US-7759507-B2 | Lipid system and methods of use | ABBOTT LABORATORIES (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100179104-A1 | SYNTHETIC NUTRITIONAL FORMULATIONS | WASSENAAR WILLEM | 2010-07-15 | — | — | US | disclosed |
| WO-2010076305-A1 | PROCESS FOR CELL-FREE PRODUCTION OF CHEMICALS | Süd-Chemie AG (DE) | 2010-07-08 | — | — | WO | disclosed |
| EP-2204453-A1 | Process for cell-free production of chemicals | Sued-Chemie AG (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-20100167936-A1 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | MERCK PATENT GESELLSCHAFT (DE) | 2010-07-01 | — | — | US | disclosed |
| US-7745694-B1 | culturing leaves, roots, fruits and seeds comprising nucleotide sequences and constructs encoding fatty acid desaturases, to generate transgenic plants that allow for the production of docosahexaenoic acid, eicosapentaenoic acid, alpha -linolenic acid, gamma-linolenic acid and arachidonic acid | MONSANTO TECHNOLOGY LLC (US) | 2010-06-29 | — | — | US | disclosed |
| CN-101744645-A | Nanometer biological robot and application thereof | INST BIOPHYSICS CN ACAD SCI | 2010-06-23 | — | — | CN | disclosed |
| US-20100154080-A1 | DELTA-8 DESATURASE GENES, ENZYMES ENCODED THEREBY AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2193205-A1 | METHOD FOR THE PRODUCTION OF A FERMENTATION PRODUCT FROM A PRETREATED LIGNOCELLULOSIC FEEDSTOCK | Iogen Energy Corporation (CA) | 2010-06-09 | — | — | EP | disclosed |
| US-20100130500-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION OF THE NEWBORN | BIOMARIN PHARMACEUTICAL INC. (US) | 2010-05-27 | — | — | US | disclosed |
| CN-1890232-B | Flavonoid derivative | MERCK PATENT GMBH | 2010-05-26 | — | — | CN | disclosed |
| US-7723503-B2 | Desaturase genes, enzymes encoded thereby, and uses thereof | ABBOTT LABORATORIES (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100119461-A1 | ANTIMICROBIAL COMPOSITION | MERCK PATENT GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100093742-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093984-A1 | EXTRACTION METHOD | WIRTH CORINNA | 2010-04-15 | — | — | US | disclosed |
| WO-2010042510-A1 | DELTA-8 DESATURASE GENES, ENZYMES ENCODED THEREBY AND USES THEREOF | ABBOTT LABORATIRES (US) | 2010-04-15 | — | — | WO | disclosed |
| CN-101686925-A | Use of ascorbic acid derivatives for the functionalization of matrices | MERCK PATENT GMBH | 2010-03-31 | — | — | CN | disclosed |
| EP-1977729-B1 | Cosmetic compositions containing pearlescent pigments | ECKART GMBH (DE) | 2010-03-03 | — | — | EP | disclosed |
| US-20100047300-A1 | PEARLESCENT PIGMENTS CONTAINING COSMETIC COMPOSITIONS | ECKART GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
| WO-2010017885-A2 | USE OF 5-(7-METHOXY-3,3-DIMETHYL-2,3-DIHYDRO-1-BENZOXEPIN-5-YL)-3-METHYL- PENTA-2,4-DIENOIC ACID AS A COSMETIC | MERCK PATENT GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010017895-A1 | USE OF INDOLE COMPOUNDS AS A COSMETIC | MERCK PATENT GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
| EP-2152685-A1 | SKIN LIGHTENING COMPOSITIONS AND METHODS | Sytheon Ltd. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20100034760-A1 | Method of Increasing the Tanning Effect of Self-tanning Substances | MERCK PATENT GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100034893-A1 | PARTICULATE UV PROTECTION AGENT | MERCK PATENT GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100028278-A1 | USE OF CHROMAN-4-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100016328-A1 | PTERIN ANALOGS | BIOMARIN PHARMACEUTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2144590-A1 | SKIN TREATMENT COMPOSITIONS AND METHODS | Sytheon Ltd. (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2144608-A1 | SUNSCREEN COMPOSITIONS AND METHODS | Sytheon Ltd. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20100009997-A1 | METHOD OF TREATING A METABOLIC OR NEUROPSYCHIARTY DISORDER WITH A BH4 DERIVATIVE PRODRUG | BIOMARIN PHARMACEUTICAL INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009996-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | BIOMARIN PHARMACEUTICAL INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100004209-A1 | [(4-Oxo-4H-chromen-3-yl)hydroxymethyl]- or [(4-oxo-4H-chromen-3-yl)methyl]phosphonic acid derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20090317342-A1 | USE OF FLAVONOIDS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2114944-A2 | TETRAHYDROBIOPTERIN PRODRUGS | BioMarin Pharmaceutical Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009133351-A2 | PRODUCTION OF BIOFUEL FROM TISSUE CULTURE SOURCES | ECO-RECLAIM LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275052-A1 | ADJUSTABLE MOLECULAR MOTOR MICROPOWER BIOSENSOR AND ITS APPLICATION | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2009-11-05 | — | — | US | disclosed |
| EP-2112882-A2 | ANTIMICROBIAL COMPOSITION COMPRISING ZINC OXIDE, BARIUM SULPHATE AND SILVER IONS | Merck Patent GmbH (DE) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009129859-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING, STRENGTHENING, IMPROVING, OR PROMOTING EYE HEALTH | DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH (DE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090265798-A1 | Desaturase genes and uses thereof | MUKERJI PRADIP | 2009-10-22 | — | — | US | disclosed |
| US-7604806-B2 | Use of a lyophilisate of dedifferentiated plant cells for skin depigmentation and/or lightening | BIOTECHMARINE (FR) | 2009-10-20 | — | — | US | disclosed |
| WO-2009124754-A1 | COMPOSITIONS CONTAINING CYCLIC PEPTIDES AND METHODS OF USE | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-7601717-B2 | Pterin analogs | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601757-B2 | Lipid system and methods of use | ABBOTT LABORATORIES (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090246158-A1 | ANTIOXIDANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-10-01 | — | — | US | disclosed |
| US-7592000-B2 | Method of tanning human body by mysting or immersion at elevated temperature | MERCK PATENT GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7588783-B2 | 5-Hydroxy-7-methoxy-2-(4'-methoxyphenyl)-4-oxo-4H-chromen-8-yl]sulfonic acid; plant extracts; use in cosmetic for protecting skin, a pharmaceutical drug, food, or food supplement | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20090226987-A1 | Desaturase Genes, Enzymes Encoded Thereby, and Uses Thereof | MUKERJI PRADIP | 2009-09-10 | — | — | US | disclosed |
| CN-101528758-A | [(4-oxo-4h-chromen-3-yl)-hydroxy methyl]- or [(4-oxo-4h-chromen-3-yl)-methyl]-phosphonic acid derivates | MERCK PATENT GMBH (DE) | 2009-09-09 | — | — | CN | disclosed |
| US-20090220441-A1 | Nanoparticulate UV Protectant With Silicon Dioxide Coating | PFLUECKER FRANK | 2009-09-03 | — | — | US | disclosed |
| US-20090220438-A1 | CHROMEN-4-ONE DERIVATIVES AS SELF-TANNING SUBSTANCE | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | US | disclosed |
| US-20090209637-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20090196894-A1 | Self Tanning Composition | CIBA CORP. | 2009-08-06 | — | — | US | disclosed |
| US-7566714-B2 | Methods and compositions for the treatment of metabolic disorders | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-07-28 | — | — | US | disclosed |
| WO-2009088530-A1 | PTERIN ANALOG FOR TREATING BH4 RESPONSIVE CONDITION | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176790-A1 | For treating conditions responsive to tetrahydrobiopterin therapies | BIOMARIN PHARMACEUTICAL INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090175970-A1 | Stabilized Plant Extract and Its Therapeutic Use | VERITRON LIMITED (GB) | 2009-07-09 | — | — | US | disclosed |
| US-20090148919-A1 | Delta 6-Desaturase Genes and Uses Thereof | ABBOTT LABORATORIES | 2009-06-11 | — | — | US | disclosed |
| US-20090137534-A1 | Skin treatment compositions and methods | SYTHEON LIMITED | 2009-05-28 | — | — | US | disclosed |
| EP-2056782-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | Merck Patent GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-7531347-B1 | Methods and compositions for synthesis of long chain polyunsaturated fatty acids | ABBOTT LABORATORIES (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1411887-B1 | SUNSCREEN COMPOSITION | MERCK PATENT GMBH (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090098072-A1 | ANTIOXIDANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2009026706-A1 | METHOD FOR THE PRODUCTION OF A FERMENTATION PRODUCT FROM A PRETREATED LIGNOCELLULOSIC FEEDSTOCK | IOGEN ENERGY CORPORATION (CA) | 2009-03-05 | — | — | WO | disclosed |
| US-20090061490-A1 | METHOD FOR THE PRODUCTION OF A FERMENTATION PRODUCT FROM A PRETREATED LIGNOCELLULOSIC FEEDSTOCK | IOGEN ENERGY CORPORATION (CA) | 2009-03-05 | — | — | US | disclosed |
| EP-2026746-A2 | SELF TANNING COMPOSITION | Ciba Holding Inc. (CH) | 2009-02-25 | — | — | EP | disclosed |
| US-20090035238-A1 | UV FILTER CAPSULE CONTAINING AN AMINO-SUBSTITUTED HYDROXYBENZOPHENONE | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036545-A1 | Skin appearance through gene manipulation | SYTHEON LTD. | 2009-02-05 | — | — | US | disclosed |
| US-20090018136-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE | BIOMARIN PHARMACEUTICAL INC. | 2009-01-15 | — | — | US | disclosed |
| CN-101334361-A | ATP motor rotary type biosensor single molecule analysis and separation technology and method | INST BIOPHYSICS CN ACAD SCI (CN) | 2008-12-31 | — | — | CN | disclosed |
| US-20080319015-A1 | Insect Repellent Mixture | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080319050-A1 | Preparation Containing Oxidized Flavonoid Derivatives | MERCK PATENT GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008153629-A1 | SKIN LIGHTENING COMPOSITIONS AND METHODS | SYTHEON LTD. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305059-A1 | Skin lightening compositions and methods | SYTHEON LIMITED | 2008-12-11 | — | — | US | disclosed |
| CN-100439512-C | Micro-power biological sensor with adjustable molecular motor | INST BIOPHYSICS CN ACAD SCI (CN) | 2008-12-03 | — | — | CN | disclosed |
| WO-2008143761-A1 | SUNSCREEN COMPOSITIONS AND METHODS | SYTHEON LTD. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-7456270-B2 | Δ6-desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080286217-A1 | Comprising at least one UV-B or UV-A/UV-B sunblock active, at least one meroterpene including plant extracts having one or more meroterpene-enriched fractions, especially suited are Bakuchiol and derivatives of Bakuchiol, and a carrier | SYTHEON LIMITED | 2008-11-20 | — | — | US | disclosed |
| WO-2008140673-A1 | SKIN TREATMENT COMPOSITIONS AND METHODS | SYTHEON LTD. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080279793-A1 | Flavonoids as Synergists for Enhancing the Action of Self-Tanning Substances | MERCK PATENT GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080260664-A1 | Particles Functionalized with Organic Compounds | MERCK PATENT GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| WO-2008122421-A1 | PEARLESCENT PIGMENTS CONTAINING COSMETIC COMPOSITIONS | ECKART GMBH (DE) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008119428-A1 | PHOTOSTABLE COMPOSITIONS | MERCK PATENT GMBH (DE) | 2008-10-09 | — | — | WO | disclosed |
| EP-1977729-A1 | Pearlescent pigments containing cosmetic compositions | Eckart GmbH (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1965803-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE | Biomarin Pharmaceutical Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20080214667-A1 | Nucleic acid molecule; complementary to a nucleotide sequence encoding a polypeptide having elongase activity | ABBOTT LABORATORIES | 2008-09-04 | — | — | US | disclosed |
| US-20080199414-A1 | COSMETIC FORMULATION COMPRISING FLAVONOID DERIVATIVES | WIRTH CORINNA | 2008-08-21 | — | — | US | disclosed |
| US-20080193569-A1 | Extraction Method for Producing Plant Extracts, Especially Waltheria Paniculata Extracts Containing Tiliroside | MERCK PATENT GESELLSCHAFT (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1952843-A1 | Photostable organic sunscreen compounds with antioxidant properties and compositions obtained therefrom | Merck Patent GmbH (DE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008089822-A2 | ANTIMICROBIAL COMPOSITION COMPRISING ZINC OXIDE, BARIUM SULPHATE AND SILVER IONS | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |
| EP-1401259-B1 | DELTA-4 DESATURASE GENES AND USES THEREOF | ABBOTT LAB (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1480993-B1 | DESATURASE GENES, ENZYMES ENCODED THEREBY, AND USES THEREOF | ABBOTT LAB (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7405068-B2 | Pyruvate producing yeast strain | TATE & LYLE INGREDIENTS AMERICAS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080176944-A1 | Elongase Genes and Uses Thereof | MUKERJI PRADIP | 2008-07-24 | — | — | US | disclosed |
| WO-2008089008-A2 | TETRAHYDROBIOPTERIN PRODRUGS | BIOMARIN PHARMACEUTICAL INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089148-A1 | METHOD OF TREATING A METABOLIC OR NEUROPSYCHIATRY DISORDER WITH A BH4 DERIVATIVE PRODRUG | BIOMARIN PHARMACEUTICAL INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1945045-A2 | INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN | Abbott Laboratories (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080171004-A1 | Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080166308-A1 | Tanning Method | MERCK PATENT GESELLSCHAFT (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008082946-A1 | METHOD OF REDUCING THE RISK OF RETINOPHATHY OF PREMATURITY IN PRETERM INFANTS | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080152603-A1 | Antioxidants | SUSONITY Commercial GmbH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080131381-A1 | METHODS FOR PHOTOSTABILIZING INGREDIENTS WITHIN COSMETICS, PERSONAL CARE AND HOUSEHOLD PRODUCTS AND COMPOSITIONS OBTAINED THEREFROM | MERCK PATENT GESELLSCHAFT (DE) | 2008-06-05 | — | — | US | disclosed |
| US-20080124439-A1 | Nutritional supplement composition comprising creatine and method for making the same | NATURALLY SCIENTIFIC, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008064096-A2 | ELONGASE GENE AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080125487-A1 | Elongase gene and uses thereof | ABBOTT LABORATORIES | 2008-05-29 | — | — | US | disclosed |
| US-7375205-B2 | Elongase genes and uses thereof | ABBOTT LABORATORIES (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080112905-A1 | Flavonoid Complexes | MERCK PATENT GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| CN-100382796-C | Methods and compositions for providing glutamine | ABBOTT LAB (US) | 2008-04-23 | — | — | CN | disclosed |
| US-20080090832-A1 | Methods and compositions for the treatment of metabolic disorders | BIOMARIN PHARMACEUTICAL INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1108039-B1 | ELONGASE GENES AND USES THEREOF | ABBOTT LAB (US) | 2008-04-16 | — | — | EP | disclosed |
| CN-101163659-A | Antioxidants | MERCK PATENT GMBH (DE) | 2008-04-16 | — | — | CN | disclosed |
| US-7345090-B2 | Galenical formulation | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2008-03-18 | — | — | US | disclosed |
| CN-101141971-A | Stable plant extracts and therapeutic uses thereof | VERITRON LTD (GB) | 2008-03-12 | — | — | CN | disclosed |
| WO-2008025368-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-03-06 | — | — | WO | disclosed |
| US-20080044364-A1 | Flavonoid Complexes | EUROPEAN BRAND PARTICIPATIONS SA (LU) | 2008-02-21 | — | — | US | disclosed |
| US-20080045478-A1 | For skin/hair light protection; cosmetics | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080044502-A1 | USE OF AN AQUEOUS OR HYDROALCOHOLIC EXTRACT OF BAUHINIA FOR THE PREPARATION OF A COMPOSITION | WIRTH CORINNA | 2008-02-21 | — | — | US | disclosed |
| US-20080039525-A1 | Containing specific ratios of omega-3, omega-6, and omega-9 fatty acids; provides optimized ratio of essential and nonessential fatty acids that can improve glucose tolerance of glucose intolerant individual, improve insulin sensitivity of insulin resistant individual, and reduce risk of vascular disease | MUSTAD VIKKIE A | 2008-02-14 | — | — | US | disclosed |
| US-20080038213-A1 | Uv Filters | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080027133-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | CAROLA CHRISTOPHE | 2008-01-31 | — | — | US | disclosed |
| US-7323200-B2 | Calcium fortified, soy based, infant nutritional formulas | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| CN-100363490-C | Metabolically engineered micro-organisms having reduced production of undesired metabolic products | FLUXOME SCIENCES AS (DK) | 2008-01-23 | — | — | CN | disclosed |
| EP-1863506-A1 | NUTRITIONAL PRODUCTS FOR AMELIORATING SYMPTOMS OF RHEUMATOID ARTHRISTIS | ABBOTT LABORATORIES (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007137958-A2 | SELF TANNING COMPOSITION | CIBA HOLDING INC. (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070254062-A1 | Newborn infant formulas and feeding methods | UNIVERSITY COLLEGE LONDON (GB) | 2007-11-01 | — | — | US | disclosed |
| CN-101060837-A | Preparation containing oxidized flavonoid derivatives | MERCK PATENT GMBH (DE) | 2007-10-24 | — | — | CN | disclosed |
| US-7264795-B2 | Sunscreen composition | MERCK PATENT GESELLSCHAFT (DE) | 2007-09-04 | — | — | US | disclosed |
| US-7261911-B2 | Aseptically packaged, extensively hydrolyzed, liquid nutritional formula and method for making it | ABBOTT LABORATORIES | 2007-08-28 | — | — | US | disclosed |
| US-20070196290-A1 | Uv filters in powder form | MERCK PATENT GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1819340-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION OF THE NEWBORN | Biomarin Pharmaceutical Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070191305-A1 | Chromone complexes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007084754-A2 | BABY FOOD AND INFANT FORMULA COMPOSITIONS | SAKURA PROPERTIES, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070166354-A1 | Method of reducing the risk of retinopathy of prematurity in preterm infants | ABBOTT LABORATORIES | 2007-07-19 | — | — | US | disclosed |
| US-7241619-B2 | Desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070155695-A1 | Flavonoid complexes with cyclodextrins | EUROPEAN BRAND PARTICIPATIONS SA (LU) | 2007-07-05 | — | — | US | disclosed |
| EP-1802747-A2 | DELTA 6-DESATURASE GENES AND USES THEREOF | Abbott Laboratories (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1112006-B1 | ELEMENTAL ENTERAL NUTRITIONAL PRODUCT CONTAINING HYDROLYSED SOY PROTEIN AND PARTIALLY HYDROLYSED CASEINATE | ABBOTT LAB (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070141014-A1 | Formulation assistants | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
| WO-2007067570-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070134172-A1 | 5-Hydroxy-7-methoxy-2-(4'-methoxyphenyl)-4-oxo-4H-chromen-8-yl]sulfonic acid; plant extracts; use in cosmetic for protecting skin, a pharmaceutical drug, food, or food supplement | EUROPEAN BRAND PARTICIPATIONS SA (LU) | 2007-06-14 | — | — | US | disclosed |
| US-20070124837-A1 | DESATURASE GENES, ENZYMES ENCODED THEREBY, AND USES THEREOF | MUKERJI PRADIP | 2007-05-31 | — | — | US | disclosed |
| US-7220897-B2 | Δ4-desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2007050521-A2 | INFANT FORMULAS CONTAINING DOCOSAHEXAENOIC ACID AND LUTEIN | ABBOTT LABORATORIES (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070098849-A1 | Infant formulas containing docosahexaenoic acid and lutein | ABBOTT LABORATORIES | 2007-05-03 | — | — | US | disclosed |
| US-20070098668-A1 | Use of a lyophilisate of dedifferentiated plant cells for skin depigmentation and/or lightening | BIOTECHMARINE (FR) | 2007-05-03 | — | — | US | disclosed |
| US-7211656-B2 | Desaturase genes, enzymes encoded thereby, and uses thereof | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070093553-A1 | HMB compositions and uses thereof | BAXTER JEFFREY H | 2007-04-26 | — | — | US | disclosed |
| US-7208297-B2 | Δ4-desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-7205134-B2 | Δ4-desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070079754-A1 | Method of tanning human body by mysting or immersion at elevated temperature | MERCK PATENT GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070048354-A1 | Synthetic nutritional formulations | WASSENAAR WILLEM | 2007-03-01 | — | — | US | disclosed |
| EP-1656039-B1 | CALCIUM FORTIFIED SOY BASED INFANT NUTRITIONAL FORMULAS | ABBOTT LAB (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20070031538-A1 | Liquid nutritional compositions containing n-3 polyunsaturated fatty acids | ABBOTT LABORATORIES | 2007-02-08 | — | — | US | disclosed |
| EP-1747773-A2 | Photostable organic sunscreen compositions with antioxidant properties | Merck Patent GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| CN-1906204-A | Flavonoid complexes comprising cyclodextrins | MERCK PATENT GMBH (DE) | 2007-01-31 | — | — | CN | disclosed |
| CN-1890232-A | Flavonoid derivative | MERCK PATENT GMBH (DE) | 2007-01-03 | — | — | CN | disclosed |
| US-20060292093-A1 | Chromen-4-one derivatives | MERCK PATENT GMBH (DE) | 2006-12-28 | — | — | US | disclosed |
| US-7150876-B2 | Methods for stabilizing ingredients within cosmetics, personal care and household products | MERCK PATENT GMBH (DE) | 2006-12-19 | — | — | US | disclosed |
| US-20060257983-A1 | Metabolically engineered micro-organisms having reduced production of undesired metabolic products | FLUXOME SCIENCES A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| US-20060253936-A1 | Novel constructs and their use in metabolic pathway engineering | PIONEER HI-BRED INTERNATIONAL INC. (US) | 2006-11-09 | — | — | US | disclosed |
| US-20060246149-A1 | Antimicrobial pigments | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20060246115-A1 | Nutritional products for ameliorating symptoms of rheumatoid arthritis | ABBOTT LABORATORIES | 2006-11-02 | — | — | US | disclosed |
| US-7128900-B2 | Light-protection agents | MERCK PATENT GMBH (DE) | 2006-10-31 | — | — | US | disclosed |
| EP-1406582-B1 | PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM | MERCK PATENT GMBH (DE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1708690-A2 | TREATMENT OF PHENYLKETONURIAS WITH BH4 | BioMarin Pharmaceutical Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060222607-A1 | Tricyclic quinoxaline and quinoline derivatives as UV filters | PFLUCKER FRANK | 2006-10-05 | — | — | US | disclosed |
| EP-1703891-A1 | METHOD OF TANNING HUMAN BODY BY MYSTING OR IMMERSION AT ELEVATED TEMPERATURE | MERCK PATENT GmbH (DE) | 2006-09-27 | — | — | EP | disclosed |
| US-20060210697-A1 | INFANT FORMULA COMPOSITION | SAKURA PROPERTIES, LLC | 2006-09-21 | — | — | US | disclosed |
| US-20060210500-A1 | Formulations | MERCK PATENT GMBH (DE) | 2006-09-21 | — | — | US | disclosed |
| WO-2006096579-A1 | NUTRITIONAL PRODUCTS FOR AMELIORATING SYMPTOMS OF RHEUMATOID ARTHRISTIS | ABBOTT LABORATORIES (US) | 2006-09-14 | — | — | WO | disclosed |
| US-20060204632-A1 | Concentrated human milk fortifier liquid | ABBOTT LABORATORIES | 2006-09-14 | — | — | US | disclosed |
| US-7101537-B2 | Tricyclic quinoxaline and quinoline derivatives as a UV filter | MERCK PATENTGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20060194057-A1 | Silicon dioxide-coated nanoparticulate uv protectant | MERCK PATENT GMBH (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1393733-B1 | Use of flavonoid-derivatives for the treatment of atopic eczema | MERCK PATENT GMBH (DE) | 2006-08-23 | — | — | EP | disclosed |
| US-7090879-B2 | Nutritional formula containing select carotenoid combinations | ABBOTT LABORATORIES (US) | 2006-08-15 | — | — | US | disclosed |
| US-7090862-B2 | Method of improving the antioxidant status of an infant | ABBOTT LABORATORIES (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060171993-A1 | Method of improving antioxidant status of an infant | ABBOTT LABORATORIES | 2006-08-03 | — | — | US | disclosed |
| US-7070970-B2 | Nutrients, animal feeds, cosmetics; elongation of polyunsaturated fatty acid | ABBOTT LABORATORIES (US) | 2006-07-04 | — | — | US | disclosed |
| US-7067285-B2 | Desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1507855-A4 | ELONGASE GENES AND USES THEREOF | ABBOTT LAB (US) | 2006-06-21 | — | — | EP | disclosed |
| CN-1789425-A | Micro-power biological sensor with adjustable molecular motor | INST BIOPHYSICS CN ACAD SCI (CN) | 2006-06-21 | — | — | CN | disclosed |
| WO-2006063215-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION OF THE NEWBORN | BIOMARIN PHARMACEUTICAL INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1662905-A1 | LIPID SYSTEM AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006051334-A1 | PLANT CELLS AND USES THEREOF | PHYTO RESEARCH LTD (GB) | 2006-05-18 | — | — | WO | disclosed |
| EP-1656039-A1 | CALCIUM FORTIFIED SOY BASED INFANT NUTRITIONAL FORMULAS | Abbott Laboratories (US) | 2006-05-17 | — | — | EP | disclosed |
| US-7045683-B2 | Δ4-desaturase genes and uses thereof | ABBOTT LABORATORIES (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1251750-B1 | IMPROVED PEDIATRIC FORMULA AND METHODS FOR PROVIDING NUTRITION AND IMPROVING TOLERANCE | ABBOTT LAB (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1635771-A2 | COSMETIC FORMULATIONS COMPRISING ANTIMICROBIAL PIGMENTS | MERCK PATENT GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006028839-A2 | DELTA 6-DESATURASE GENES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060057169-A1 | Topical anhydrous delivery system for antioxidants | MERCK PATENT GMBH (DE) | 2006-03-16 | — | — | US | disclosed |
| EP-1633818-A2 | ANTIMICROBIAL PIGMENTS | MERCK PATENT GmbH (DE) | 2006-03-15 | — | — | EP | disclosed |
| EP-1480993-A4 | DESATURASE GENES, ENZYMES ENCODED THEREBY, AND USES THEREOF | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20060045856-A1 | Composition containing a dihydroxyacetone precursor | MERCK PATENT GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20060048244-A1 | Delta6-desaturase genes and uses thereof | ABBOTT LABORATORIES | 2006-03-02 | — | — | US | disclosed |
| US-20060040946-A1 | Methods and compositions for the treatment of metabolic disorders | BIOMARIN PHARMACEUTICAL INC. (US) | 2006-02-23 | — | — | US | disclosed |
| US-20060039937-A1 | Composition having antioxidant properties | MERCK PATENT GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20060014019-A1 | Non-flak coated colouring pigment and method for the production and use thereof | KUEBELBECK ARMIN | 2006-01-19 | — | — | US | disclosed |
| US-20060002875-A1 | Diffractive colorants for cosmetics | MERCK PATENT GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1202744-B1 | PRODUCTION OF rhPBGD | ZYMENEX AS (DK) | 2006-01-04 | — | — | EP | disclosed |
| CN-1717481-A | Metabolically engineered micro-organisms having reduced production of undesired metabolic products | FLUXOME SCIENCES AS (DK) | 2006-01-04 | — | — | CN | disclosed |
| EP-0975766-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | CALGENE LLC (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1598422-A2 | Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants | Calgene LLC (US) | 2005-11-23 | — | — | EP | disclosed |
| CN-1226416-C | Method for producing baccatin | INDENA SPA (IT) | 2005-11-09 | — | — | CN | disclosed |
| CN-1694928-A | Non-platelet coating color pigments, method for the production thereof and use thereof | MERCK PATENT GMBH (DE) | 2005-11-09 | — | — | CN | disclosed |
| US-20050244349-A1 | Methods for stabilizing ingredients within cosmetics, personal care and household products | SUSONITY Commercial GmbH (DE) | 2005-11-03 | — | — | US | disclosed |
| EP-1591099-A2 | Methods for stabilizing ingredients within cosmetics, personal care and household products | MERCK PATENT GmbH (DE) | 2005-11-02 | — | — | EP | disclosed |
| US-20050215640-A1 | HMB compositions and uses thereof | ABBOTT LABORATORIES | 2005-09-29 | — | — | US | disclosed |
| US-20050208179-A1 | Nutritional formula containing select carotenoid combinations | ABBOTT LABORATORIES | 2005-09-22 | — | — | US | disclosed |
| EP-0980214-B1 | CONTROLLED-RELEASE FORMULA FOR PERFORMANCE DRINKS | BOOTH GARCIA PAUL (CA) | 2005-09-21 | — | — | EP | disclosed |
| EP-1565554-A1 | METABOLICALLY ENGINEERED MICRO-ORGANISMS HAVING REDUCED PRODUCTION OF UNDESIRED METABOLIC PRODUCTS | Fluxome Sciences AS (DK) | 2005-08-24 | — | — | EP | disclosed |
| US-20050175759-A1 | Newborn infant formulas and feeding methods | UNIVERSITY COLLEGE LONDON (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1558207-A1 | TOPICAL ANHYDROUS DELIVERY SYSTEM FOR ANTIOXIDANTS | MERCK PATENT GmbH (DE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1555896-A1 | METHODS AND COMPOSITIONS FOR PROVIDING GLUTAMINE | Abbott Laboratories (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6913916-B1 | Elongase genes and uses thereof | ABBOTT LABORATORIES (US) | 2005-07-05 | — | — | US | disclosed |
| WO-2005058270-A1 | METHOD OF TANNING HUMAN BODY BY MYSTING OR IMMERSION AT ELEVATED TEMPERATURE | MERCK PATENT GMBH (DE) | 2005-06-30 | — | — | WO | disclosed |
| EP-0996732-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS IN PLANTS | CALGENE LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6903134-B2 | Formulation comprising benzofuranone derivatives for protection against oxidative stress | MERCK PATENT GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| WO-2005049000-A2 | TREATMENT OF PHENYLKETONURIAS WITH BH4 | BIOMARIN PHARMACEUTICAL INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005025334-A1 | LIPID SYSTEM AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059136-A1 | Pyruvate producing yeast strain | A.E. STALEY MANUFACTURING CO. | 2005-03-17 | — | — | US | disclosed |
| US-20050054724-A1 | Lipid system and methods of use | ABBOTT LABORATORIES | 2005-03-10 | — | — | US | disclosed |
| WO-2005018343-A1 | CALCIUM FORTIFIED SOY BASED INFANT NUTRITIONAL FORMULAS | ABBOTT LABORATORIES (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050042329-A1 | Calcium fortified, soy based, infant nutritional formulas | ABBOTT LABORATORIES | 2005-02-24 | — | — | US | disclosed |
| US-20050043398-A1 | Use of chromen-4-one derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1507855-A2 | ELONGASE GENES AND USES THEREOF | Abbott Laboratories (US) | 2005-02-23 | — | — | EP | disclosed |
| US-6858416-B2 | Human desaturase gene and uses thereof | ABBOTT LABORATORIES (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050031736-A1 | Infant formulas containing lutein compounds | NGUYEN MINHTHY LE (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050019426-A1 | For care, protection from aging of skin and hair, use in treatment of various skin disorders such as leukoplakia, eczema, keratosis, psoriasis, or to promote wound healing | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| US-20050009140-A1 | Elongase genes and uses thereof | MUKERJI PRADIP (US) | 2005-01-13 | — | — | US | disclosed |
| US-20050003442-A1 | Delta4-desaturase genes and uses thereof | MUKERJI PRADIP (US) | 2005-01-06 | — | — | US | disclosed |
| US-20050005329-A1 | Delta4-desaturase genes and uses thereof | MUKERJI PRADIP (US) | 2005-01-06 | — | — | US | disclosed |
| US-20050005328-A1 | Delta4-desaturase genes and uses thereof | MUKERJI PRADIP (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1480993-A2 | DESATURASE GENES, ENZYMES ENCODED THEREBY, AND USES THEREOF | ABBOTT LABORATORIES (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6811801-B2 | ADDING FREE LUTEIN, LUTEIN ESTERS, FREE ZEAXANTHIN, ZEAXANTHIN ESTERS, ISOMERIC FORMS, OR ACCCEPTABLE SALTS; MASKING BROWN AND GRAY HUES WITHOUT YELLOW COLORING; DISCOLORATION INHIBITION | ABBOTT LABORATORIES | 2004-11-02 | — | — | US | disclosed |
| WO-2004092283-A2 | ANTIMICROBIAL PIGMENTS | MERCK PATENT GMBH (DE) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004091567-A2 | COSMETIC FORMULATIONS COMPRISING ANTIMICROBIAL PIGMENTS | MERCK PATENT GMBH (DE) | 2004-10-28 | — | — | WO | disclosed |
| US-20040202624-A1 | Galenical formulation | PFLUECKER FRANK (DE) | 2004-10-14 | — | — | US | disclosed |
| EP-1007691-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | CALGENE LLC (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040175335-A1 | Sunscreen composition | MERCK PATENT GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040170582-A1 | Sunscreen composition | MERCK PATENT GESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
| US-6774111-B1 | MIXTURE OF FRUCTOSE AND AT LEAST ONE READILY DIGESTIBLE GLUCOSE POLYMER SOURCE | ABBOTT LABORATORIES | 2004-08-10 | — | — | US | disclosed |
| WO-2004048559-A1 | METABOLICALLY ENGINEERED MICRO-ORGANISMS HAVING REDUCED PRODUCTION OF UNDESIRED METABOLIC PRODUCTS | FLUXOME SCIENCES A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102446-A1 | Tricyclic quinoxaline derivatives as a uv filter | MERCK PATENT GMBH (DE) | 2004-05-27 | — | — | US | disclosed |
| WO-2004041234-A1 | TOPICAL ANHYDROUS DELIVERY SYSTEM FOR ANTIOXIDANTS | MERCK PATENT GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
| US-20040091433-A1 | Light-protection agents | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| US-20040081675-A1 | Cosmetic formulations containing flavonoid derivatives | MERCK PATENT GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1411887-A2 | SUNSCREEN COMPOSITION | MERCK PATENT GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
| EP-1411888-A2 | SUNSCREEN COMPOSITION | MERCK PATENT GmbH (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20040076699-A1 | Topical anhydrous delivery system | EMD CHEMICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004032653-A1 | METHODS AND COMPOSITIONS FOR PROVIDING GLUTAMINE | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1406582-A1 | PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM | MERCK PATENT GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-20040067894-A1 | Preparation having antioxidant properties | MERCK PATENT GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| WO-2002081668-A9 | DESATURASE GENES AND USES THEREOF | ABBOTT LAB (US) | 2004-04-08 | — | — | WO | disclosed |
| EP-1401259-A2 | DELTA-4 DESATURASE GENES AND USES THEREOF | Abbott Laboratories (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040053860-A1 | Flavonoid derivatives for the treatment of eczema | MERCK PATENT GMBH (DE) | 2004-03-18 | — | — | US | disclosed |
| EP-1392823-A2 | DESATURASE GENES AND USES THEREOF | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1053345-B1 | METHOD FOR PRODUCING BACCATIN | INDENA SPA (IT) | 2004-03-03 | — | — | EP | disclosed |
| EP-1393733-A1 | Flavonoid-derivate for the treatment of eczema | MERCK PATENT GmbH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-0994657-B1 | PALATABLE ELEMENTAL MEDICAL FOOD | ABBOTT LAB (US) | 2004-01-28 | — | — | EP | disclosed |
| CN-1468313-A | Novel constructs and their use in metabolic pathway engineering | �����ɷ� | 2004-01-14 | — | — | CN | disclosed |
| US-6677145-B2 | ISOLATING A NUCLEOTIDE SEQUENCE HAVING SPECIFIC SEQUENCE, CONSTRUCTING A VECTOR CONSISTS OF AN ISOLATED NUCLEOTIDE SEQUENCE OPERABLY LINKED TO A PROMOTER, INTRODUCING THE VECTOR INTO HOST CELL FOR EXPRESSION OF ELONGASE ENZYME | ABBOTT LABORATORIES | 2004-01-13 | — | — | US | disclosed |
| WO-2003102138-A2 | ELONGASE GENES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030207886-A1 | Preparation containing quinoxaline derivatives | MERCK PATENT GMBH (DE) | 2003-11-06 | — | — | US | disclosed |
| US-6635451-B2 | Conversion of dihomo-gamma linolenic acid (DGLA) to arachidonic acid and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA); Delta 6 desaturase and Delta 5 desaturase | ABBOTT LABORATORIES | 2003-10-21 | — | — | US | disclosed |
| US-20030196217-A1 | Desaturase genes, enzymes encoded thereby, and uses thereof | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
| US-20030190733-A1 | Desaturase genes and uses thereof | MUKERJI PRADIP (US) | 2003-10-09 | — | — | US | disclosed |
| US-20030177508-A1 | Elongase genes and uses thereof | MUKERJI PRADIP | 2003-09-18 | — | — | US | disclosed |
| US-20030167525-A1 | Desaturase genes and uses thereof | ABBOTT LABORATORIES | 2003-09-04 | — | — | US | disclosed |
| US-20030163845-A1 | Elongase genes and uses thereof | ABBOTT LABORATORIES | 2003-08-28 | — | — | US | disclosed |
| US-20030157144-A1 | Conversion of dihomo-gamma linolenic acid (DGLA) to arachidonic acid and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA); Delta 6 desaturase and Delta 5 desaturase | ABBOTT LABORATORIES | 2003-08-21 | — | — | US | disclosed |
| WO-2003064596-A2 | DESATURASE GENES, ENZYMES ENCODED THEREBY, AND USES THEREOF | ABBOTT LABORATORIES (US) | 2003-08-07 | — | — | WO | disclosed |
| US-6596865-B1 | Removing phosphoric acid and thiamine triphosphate by flowing over unsaturated nitrogen-heterocycle resin adsorber | MERCK PATENT GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
| US-6596707-B2 | To treat and prevent infections caused by bacterial toxins, in particular, Shiga toxins and Shiga-like toxins | ABBOTT LABORATORIES | 2003-07-22 | — | — | US | disclosed |
| US-20030134400-A1 | Delta4-desaturase genes and uses thereof | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | disclosed |
| US-6593476-B2 | Using 2-arylbenzimidazolesulfonic acid | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2003-07-15 | — | — | US | disclosed |
| US-6589576-B2 | Includes xanthan gum which improves tolerance (e.g. less gastrointestinal symptoms such as emesis, stool patterns and gas) | ABBOTT LABORATORIES | 2003-07-08 | — | — | US | disclosed |
| WO-2003049555-A1 | METHODS AND COMPOSITIONS FOR BRIGHTENING THE COLOR OF THERMALLY PROCESSED NUTRTIONALS | ABBOTT LABORATORIES (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1317535-A2 | CONSTRUCTS AND THEIR USE IN METABOLIC PATHWAY ENGINEERING | Maxygen, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030104596-A1 | human desaturase gene and uses thereof | MUKERJI PRADIP (US) | 2003-06-05 | — | — | US | disclosed |
| EP-1309699-A2 | ELONGASE GENES AND USES THEREOF | Abbott Laboratories (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6562778-B1 | Solubilizing water-insoluble substances with combinations of alk(en)yl oligoglycosides and polyol | COGNIS DEUTSCHLAND GMBH (DE) | 2003-05-13 | — | — | US | disclosed |
| US-20030082754-A1 | Delta4 - desaturase genes and uses thereof | ABBOTT LABORATORIES | 2003-05-01 | — | — | US | disclosed |
| US-20030060426-A1 | Formulation for protection against oxidative stress containing benzofuranone derivatives | MERCK PATENT GMBH (DE) | 2003-03-27 | — | — | US | disclosed |
| US-20030040503-A1 | Monovalent saccharides and uses thereof | ABBOTT LABORATORIES | 2003-02-27 | — | — | US | disclosed |
| WO-2003011238-A2 | SUNSCREEN COMPOSITION | MERCK PATENT GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011239-A2 | SUNSCREEN COMPOSITION | MERCK PATENT GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003007906-A1 | PHOTOSTABLE ORGANIC SUNSCREEN COMPOUNDS WITH ANTIOXIDANT PROPERTIES AND COMPOSITIONS OBTAINED THEREFROM | MERCK PATENT GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
| EP-1140953-B1 | METHOD OF PURIFYING THIAMINE PHOSPHATES | MERCK PATENT GMBH (DE) | 2003-01-22 | — | — | EP | disclosed |
| EP-1267639-A1 | CARBOHYDRATE SYSTEM AND A METHOD FOR PROVIDING NUTRITON TO A DIABETIC | Abbott Laboratories (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0625197-B1 | DNA ENCODING KAPPA-CASEIN, PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF | SYMBICOM AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020176911-A1 | Pediatric formula and methods for providing nutrition and improving tolerance | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| WO-2002090493-A2 | Δ4-DESATURASE GENES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1251750-A1 | IMPROVED PEDIATRIC FORMULA AND METHODS FOR PROVIDING NUTRITION AND IMPROVING TOLERANCE | Abbott Laboratories (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-0980214-A4 | CONTROLLED-RELEASE FORMULA FOR PERFORMANCE DRINKS | BOOTH GARCIA PAUL (CA) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002081668-A2 | DESATURASE GENES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020138874-A1 | Elongase genes and uses thereof | ABBOTT LABORATORIES | 2002-09-26 | — | — | US | disclosed |
| US-20020132308-A1 | Novel constructs and their use in metabolic pathway engineering | MPEP @ PAGE 300-M | 2002-09-19 | — | — | US | disclosed |
| US-6440401-B1 | 2-PHENYLBENZIMIDAZOLEDI- AND TRISULFONIC ACIDS; COSMETIC FORMULATIONS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-08-27 | — | — | US | disclosed |
| US-6440470-B2 | Elemental enteral nutritional product | ABBOTT LABORATORIES | 2002-08-27 | — | — | US | disclosed |
| US-6432684-B1 | HUMAN NUCLEOTIDE SEQUENCE ENCODE A POLYPEPTIDE FOR DENATURING POLYUNSATURATED FATTY ACID | ABBOTT LABORATORIES | 2002-08-13 | — | — | US | disclosed |
| US-20020106338-A1 | Galenical formulation | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-08-08 | — | — | US | disclosed |
| US-6428990-B1 | CONVERSION OF DIHOMO-GAMMA-LINOLENIC ACID TO ARACHIDONIC ACID AND 20:4N-3 TO EICOSAPENTAENOIC ACID BY HOST CELL TRANSFORMED TO EXPRESS HUMAN DELTA5-DESATURASE ENZYME | ABBOTT LABORATORIES | 2002-08-06 | — | — | US | disclosed |
| US-6403349-B1 | ELONGATION OF POLYUNSATURATED FATTY ACID SUCH AS LINOLENIC ACID TO DIHOMOGAMMA LINOLENIC ACID; NUCLEOTIDE SEQUENCE ENCODES POLYPEPTIDE; GENETIC ENGINEERING; ANIMAL FEEDS, NUTRIENTS, COSMETICS | ABBOTT LABORATORIES | 2002-06-11 | — | — | US | disclosed |
| US-20020055532-A1 | UV-B filter | MERCK PATENT GESELLSCHAFT (DE) | 2002-05-09 | — | — | US | disclosed |
| EP-1196608-A2 | NOVEL ANTIFUNGAL AGENTS AND FUNGICIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | Aventis Research & Technologies GmbH & Co. KG (DE) | 2002-04-17 | — | — | EP | disclosed |
| US-6372782-B1 | PROTEIN SOURCE OF SOY PROTEIN, LIPID AND CARBOHYDRATE WITH VITAMINS AND MINERALS LOW FAT, VITAMIN/MINERAL FORTIFIED SOY-BASED ORAL NUTRITIONAL PRODUCT USEFUL FOR PROVIDING SOY | ABBOTT LABORATORIES | 2002-04-16 | — | — | US | disclosed |
| WO-2002016583-A2 | CONSTRUCTS AND THEIR USE IN METABOLIC PATHWAY ENGINEERING | MAXYGEN, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| US-20020016349-A1 | UV-B filters | MERCK PATENT GESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| US-20020013474-A1 | Process for the preparation of UV filter substances | MERCK PATENT GESELLSCHAFT | 2002-01-31 | — | — | US | disclosed |
| WO-2002008401-A2 | ELONGASE GENES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1140953-A1 | METHOD OF PURIFYING THIAMINE PHOSPHATES | MERCK PATENT GmbH (DE) | 2001-10-10 | — | — | EP | disclosed |
| EP-1141252-A2 | HUMAN DESATURASE GENE AND USES THEREOF | ABBOTT LABORATORIES (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0675689-B1 | MEDICAL FOODS FOR THE NUTRITIONAL SUPPORT OF CHILD/ADULT METABOLIC DISEASES | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001067895-A1 | CARBOHYDRATE SYSTEM AND A METHOD FOR PROVIDING NUTRITON TO A DIABETIC | ABBOTT LABORATORIES (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001056406-A1 | IMPROVED PEDIATRIC FORMULA AND METHODS FOR PROVIDING NUTRITION AND IMPROVING TOLERANCE | ABBOTT LABORATORIES (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6258387-B1 | SOY PROTEIN HYDROLYZATE, HYDROLYZED CASEINATE, ARGININE, LIPID, AND CARBOHYDRATE; MALABSORPTION TREATMENT; GASTROINTESTINAL DISORDERS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1108039-A2 | ELONGASE GENES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6245803-B1 | ENTERAL ADMINISTERING NUTRIENTS | ABBOTT LABORATORIES | 2001-06-12 | — | — | US | disclosed |
| US-6232094-B1 | GENE EXPRESSION; INFANT FORMULA | SYMBICOM AKTIEBOLAG (SE) | 2001-05-15 | — | — | US | disclosed |
| WO-2000012720-A9 | ELONGASE GENES AND USES THEREOF | ABBOTT LAB (US) | 2001-04-19 | — | — | WO | disclosed |
| CN-1290305-A | Method for producing baccatin | INDENA SPA (IT) | 2001-04-04 | — | — | CN | disclosed |
| US-6207203-B1 | WATER SOLUBLE, LOW FAT, VITAMIN AND MINERAL FORTIFIED INSTANT COFFEE DRINK | ABBOTT LABORATORIES | 2001-03-27 | — | — | US | disclosed |
| US-6194379-B1 | Elemental enteral formula | ABBOTT LABORATORIES | 2001-02-27 | — | — | US | disclosed |
| WO-2001002587-A2 | NOVEL ANTIFUNGAL AGENTS AND FUNGICIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 2001-01-11 | — | — | WO | disclosed |
| EP-1053345-A1 | METHOD FOR PRODUCING BACCATIN | INDENA S.p.A. (IT) | 2000-11-22 | — | — | EP | disclosed |
| US-6150399-A | COMPRISING ISOFLAVONE ENRICHED SOY PROTEIN SOURCE; A CALCIUM SOURCE PROVIDING 35% OF THE RDI FOR CALCIUM; A SOLUBLE CALCIUM SOURCE AT GIVEN MAXIMUM LEVEL; AND A STABILIZER SYSTEM OF CELLULOSE GEL AND CARRAGEENAN; THERMOSTABILITY | ABBOTT LABORATORIES (US) | 2000-11-21 | — | — | US | disclosed |
| US-6143731-A | USEFUL IN TREATMENT OF DIETARY DISORDERS, AS DIETARY ADDITIVES TO PROVIDE A SOURCE OF FIBER AND OF SHORT CHAIN FATTY ACIDS, TO REDUCE LEVEL OF SERUM CHOLESTEROL, INCREASE HDL CHOLESTEROL LEVELS AND AS BULKING AGENTS IN HUMANS AND ANIMALS | THE COLLABORATIVE GROUP, LTD. (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000040705-A2 | HUMAN DESATURASE GENE AND USES THEREOF | ABBOTT LABORATORIES (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000035927-A1 | METHOD OF PURIFYING THIAMINE PHOSPHATES | MERCK PATENT GMBH (DE) | 2000-06-22 | — | — | WO | disclosed |
| EP-1007691-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | Calgene LLC (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0996732-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS IN PLANTS | Calgene LLC (US) | 2000-05-03 | — | — | EP | disclosed |
| CN-1252099-A | Methods and compositions for synthesizing long chain polyunsaturated fatty acids | CALIFORNIA GENES CORP (US) | 2000-05-03 | — | — | CN | disclosed |
| EP-0994657-A1 | PALATABLE ELEMENTAL MEDICAL FOOD | Abbott Laboratories (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-2000020603-A1 | ALTERED FATTY ACID BIOSYNTHESIS IN INSECT CELLS USING DELTA FIVE DESATURASE | ABBOTT LABORATORIES (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020602-A2 | DELTA 6 AND DELTA 12 DESATURASES AND MODIFIED FATTY ACID BIOSYNTHESIS AND PRODUCTS PRODUCED THEREFROM | ABBOTT LABORATORIES (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000012720-A2 | ELONGASE GENES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0980214-A1 | CONTROLLED-RELEASE FORMULA FOR PERFORMANCE DRINKS | Booth, Garcia Paul (CA) | 2000-02-23 | — | — | EP | disclosed |
| EP-0975766-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | Calgene LLC (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6020324-A | Glucan dietary additives | THE COLLABORATIVE GROUP, LTD. (US) | 2000-02-01 | — | — | US | disclosed |
| US-5980968-A | A SPORT DRINKS, ELECTROLYTE DRINKS COMPRISING AT LEAST ONE CARBOHYDRATE AND AT LEAST TWO BIODEGRADABLE POLYMERS SELECTED FROM THE GROUP CONSISTING OF COPOLYMERS OF SUCROSE AND EPICHLOROHYDRIN, POLYOXYETHYLENE GLYCOL | BOOTH GARCIA PAUL (US) | 1999-11-09 | — | — | US | disclosed |
| US-5942274-A | COMBINING RECOMBINANT HUMAN ALPHA-LACTALBUMIN, RECOMBINANT HUMAN BETA-CASEIN, OR BOTH WITH LIPIDS FROM NON-HUMAN SOURCES, VITAMINS, MINERALS, AND OTHER NUTRIENTS FORMING INFANT FORMULA | SLATTERY CHARLES W (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999040216-A1 | METHOD FOR PRODUCING BACCATIN | INDENA S.P.A. (IT) | 1999-08-12 | — | — | WO | disclosed |
| WO-1998046763-A9 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | — | 1999-03-18 | — | — | WO | disclosed |
| WO-1998046764-A9 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS IN PLANTS | — | 1999-03-18 | — | — | WO | disclosed |
| WO-1998046765-A9 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | — | 1999-03-18 | — | — | WO | disclosed |
| WO-1999001044-A1 | PALATABLE ELEMENTAL MEDICAL FOOD | ABBOTT LABORATORIES (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1998046765-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | CALGENE LLC (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046763-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS | CALGENE LLC (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046764-A1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATED FATTY ACIDS IN PLANTS | CALGENE LLC (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998020755-A1 | CONTROLLED-RELEASE FORMULA FOR PERFORMANCE DRINKS | BOOTH GARCIA PAUL (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5739407-A | GENETIC ENGINEERING DNA ENCODES A POLYPEPTIDE | SYMBICOM AKTIEBOLAG (SE) | 1998-04-14 | — | — | US | disclosed |
| US-5658714-A | SOLUBILIZING; PASSING SLURRY THROUGH MEMBRANE WHICH REJECTS PHYTATE AND ALUMINUM; IMPROVED NUTRITIONAL PRODUCT | ABBOTT LABORATORIES (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0501117-B1 | Isolation of proteins by ultrafiltration | ABBOTT LAB (US) | 1996-01-03 | — | — | EP | disclosed |
| EP-0625197-A1 | DNA ENCODING KAPPA-CASEIN, PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF | SYMBICOM AB (SE) | 1994-11-23 | — | — | EP | disclosed |
| US-5340603-A | High calorie, high fat formula | ABBOTT LABORATORIES (US) | 1994-08-23 | — | — | US | disclosed |
| US-5326569-A | Medical foods for the nutritional support of child/adult metabolic diseases | ABBOTT LABORATORIES (US) | 1994-07-05 | — | — | US | disclosed |
| EP-0599978-A1 | GENE ENCODING A HUMAN BETA-CASEIN PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF IN AN INFANT FORMULA | SYMBICOM AB (SE) | 1994-06-08 | — | — | EP | disclosed |
| EP-0440725-B1 | GLUCAN DIETARY ADDITIVES | ALPHA BETA TECHNOLOGY (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0591277-A1 | LIQUID NUTRITIONAL PRODUCT. | ABBOTT LAB (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0591267-A1 | BLEND OF DIETARY FIBER FOR NUTRITIONAL PRODUCTS. | ABBOTT LAB (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5294539-A | Culturing candida or hansenula; disrupting, removing debris, chromatography, concentration, ultrafiltration, drying by fluidized bed granulation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-03-15 | — | — | US | disclosed |
| EP-0591277-A4 | LIQUID NUTRITIONAL PRODUCT. | ABBOTT LAB (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5270450-A | Low aluminum, low phytate | ABBOTT LABORATORIES (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0591267-A4 | BLEND OF DIETARY FIBER FOR NUTRITIONAL PRODUCTS. | ABBOTT LAB (US) | 1993-10-26 | — | — | EP | disclosed |
| WO-1993015196-A1 | DNA ENCODING KAPPA-CASEIN, PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF | SYMBICOM AKTIEBOLAG (SE) | 1993-08-05 | — | — | WO | disclosed |
| WO-1993004172-A2 | GENE ENCODING A HUMAN BETA-CASEIN PROCESS FOR OBTAINING THE PROTEIN AND USE THEREOF IN AN INFANT FORMULA | SYMBICOM AKTIEBOLAG (SE) | 1993-03-04 | — | — | WO | disclosed |
| WO-1993000020-A1 | BLEND OF DIETARY FIBER FOR NUTRITIONAL PRODUCTS | ABBOTT LABORATORIES (US) | 1993-01-07 | — | — | WO | disclosed |
| WO-1993000019-A1 | LIQUID NUTRITIONAL PRODUCT | ABBOTT LABORATORIES (US) | 1993-01-07 | — | — | WO | disclosed |
| EP-0501117-A1 | Isolation of proteins by ultrafiltration | ABBOTT LABORATORIES (US) | 1992-09-02 | — | — | EP | disclosed |
| US-5104677-A | Liquid nutritional product | ABBOTT LABORATORIES (US) | 1992-04-14 | — | — | US | disclosed |
| US-5085883-A | Gum arebic, sodium caroxymethyl cellulose and oat hull; normalize bowel functions | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
| US-5047223-A | Separation of phosphoric acid from aqueous solutions of thiamine phosphates | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0440725-A1 | GLUCAN DIETARY ADDITIVES. | ALPHA BETA TECHNOLOGY (US) | 1991-08-14 | — | — | EP | disclosed |
| US-4962094-A | Providing fiber source | ALPHA BETA TECHNOLOGY, INC. (US) | 1990-10-09 | — | — | US | disclosed |
| CN-1044892-A | With the vitamin in the microballon release addition method supplementary diet | WRIGLEY W M JUN CO (US) | 1990-08-29 | — | — | CN | disclosed |
| WO-1990009108-A1 | ENHANCED FOOD VITAMIN ADDITION BY MICROBEAD DELIVERY | WM. WRIGLEY JR. COMPANY (US) | 1990-08-23 | — | — | WO | disclosed |
| WO-1990004334-A1 | GLUCAN DIETARY ADDITIVES | ALPHA BETA TECHNOLOGY (US) | 1990-05-03 | — | — | WO | disclosed |
| EP-0236855-A1 | Pharmaceutical composition | MERCK PATENT GmbH (DE) | 1987-09-16 | — | — | EP | disclosed |
| US-4303692-A | TAURINE ADDITIVE | ABBOTT LABORATORIES | 1981-12-01 | — | — | US | disclosed |
| EP-0005559-B1 | PHENYLAMINOTHIOPHENE ACETIC ACIDS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-11-04 | — | — | EP | disclosed |
| EP-0005559-A1 | Phenylaminothiophene acetic acids, process for their preparation and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1979-11-28 | — | — | EP | disclosed |
| US-4096180-A | Fluorodehydroxylation of serine | MERCK & CO., INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509442-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIFC1 | HSP90AA1 615/4885KDM4E 1701/4885TKT 1514/4885 |
| US-20200360374-A1 | DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS | KRAS, NRAS, HRAS | HSP90AA1 1773/4885KDM4E 3487/4885TKT 2099/4885 |
| US-20180020661-A1 | POWDER FORMULATION CONTAINING INSECT REPELLENT | WAPL, ACHE, BPHL | HSP90AA1 3328/4885KDM4E 1139/4885TKT 3517/4885 |
| US-20240317715-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | HSP90AA1 255/4885KDM4E 1372/4885TKT 261/4885 |
| US-20100093742-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | HSP90AA1 1559/4885KDM4E 4678/4885TKT 299/4885 |
| US-20110142777-A1 | Use of indole compounds as a cosmetic | IDO1, TYR, IDO2 | HSP90AA1 4510/4885KDM4E 136/4885TKT 3338/4885 |
| US-20150306002-A1 | 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES | S100A4, CUTA, OCIAD1 | HSP90AA1 679/4885KDM4E 872/4885TKT 3875/4885 |
| US-20130164230-A1 | 2,2'-FUROIN DERIVATIVES AND USE THEREOF TO LIGHT SKIN | TYR, ALDH1A2, MC1R | HSP90AA1 4394/4885KDM4E 4348/4885TKT 594/4885 |
| US-11737997-B2 | Method to increase cellular availability of calcium in skin cells and mixtures | CA2, CHERP, SLC8B1 | HSP90AA1 2951/4885KDM4E 4533/4885TKT 3004/4885 |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | HSP90AA1 2279/4885KDM4E 3093/4885TKT 4182/4885 |
| US-20200030324-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSP90AA1 3441/4885KDM4E 4110/4885TKT 3493/4885 |
| US-20230028414-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | KRAS, NRAS, HRAS | HSP90AA1 2536/4885KDM4E 3775/4885TKT 2777/4885 |
| US-20150182432-A1 | PHENYL KETONE DERIVATIVES AS SELF-TANNING AGENTS | TYR, PAH, MITF | HSP90AA1 495/4885KDM4E 277/4885TKT 18/4885 |
| US-20070134172-A1 | 5-Hydroxy-7-methoxy-2-(4'-methoxyphenyl)-4-oxo-4H-chromen-8-yl]sulfonic acid; plant extracts; use in cosmetic for protecting skin, a pharmaceutical drug, food, or food supplement | CYP8B1, TYR, CUTA | HSP90AA1 2803/4885KDM4E 122/4885TKT 2242/4885 |
| US-11931387-B2 | Methods and compositions relating to microbial treatment and diagnosis of disorders | FAH, LIPC, ASAH2 | HSP90AA1 1582/4885KDM4E 4398/4885TKT 113/4885 |
| US-20250179068-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | HSP90AA1 4258/4885KDM4E 2685/4885TKT 1477/4885 |
| US-20080152603-A1 | Antioxidants | GPX4, GPX1, CAT | HSP90AA1 1082/4885KDM4E 3685/4885TKT 1100/4885 |
| US-20100009996-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | PAH, BHMT, FAH | HSP90AA1 1851/4885KDM4E 375/4885TKT 14/4885 |
| US-20170081339-A1 | COMPOSITIONS AND METHODS FOR RESTORING EPIDERMAL INTEGRITY AND FUNCTION AND TREATING DERMATOLOGICAL DISEASES | ASAH2, CUTA, ASAH1 | HSP90AA1 1971/4885KDM4E 4260/4885TKT 1769/4885 |
| US-20200405674-A1 | METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES | CA2, CHERP, ORAI1 | HSP90AA1 3344/4885KDM4E 4481/4885TKT 2515/4885 |
| US-20100016328-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | HSP90AA1 1559/4885KDM4E 4678/4885TKT 299/4885 |
| US-20200339532-A1 | PDE4D INHIBITORS | PDE4A, PDE4B, PDE4D | HSP90AA1 2135/4885KDM4E 1231/4885TKT 1931/4885 |
| US-20230248729-A1 | DOSING REGIMEN OF KRAS G12C INHIBITOR | KRAS, NRAS, HRAS | HSP90AA1 2536/4885KDM4E 3775/4885TKT 2777/4885 |
| US-12441705-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | HSP90AA1 298/4885KDM4E 1251/4885TKT 238/4885 |
| US-11312725-B2 | Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases | ASAH2, CUTA, ASAH1 | HSP90AA1 1971/4885KDM4E 4260/4885TKT 1769/4885 |
| US-20040091433-A1 | Light-protection agents | CBR1, CYC1, C9 | HSP90AA1 1791/4885KDM4E 4503/4885TKT 3968/4885 |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSP90AA1 3470/4885KDM4E 4105/4885TKT 3459/4885 |
| US-20080090832-A1 | Methods and compositions for the treatment of metabolic disorders | PAH, BHMT, FAH | HSP90AA1 1851/4885KDM4E 375/4885TKT 14/4885 |
| US-20210386798-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | FAH, LIPC, ASAH2 | HSP90AA1 1582/4885KDM4E 4398/4885TKT 113/4885 |
| US-11234914-B2 | Monosubstituted urea derivatives as a self-tanning substance | SLC14A1, TYR, UROD | HSP90AA1 1561/4885KDM4E 1719/4885TKT 589/4885 |
| US-20200030214-A1 | USE OF COMPATIBLE SOLUTES | SLC9A5, SLC9A1, SLC9A3 | HSP90AA1 838/4885KDM4E 3005/4885TKT 3433/4885 |
| US-20090137534-A1 | Skin treatment compositions and methods | CUTA, KRT18, CYP8B1 | HSP90AA1 670/4885KDM4E 2925/4885TKT 357/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSP90AA1 3470/4885KDM4E 4105/4885TKT 3459/4885 |
| US-20150265516-A1 | COMPOSITIONS CONTAINING CYCLIC PEPTIDES AND METHODS OF USE | CUTA, NGLY1, CALCA | HSP90AA1 2303/4885KDM4E 4590/4885TKT 3989/4885 |
| US-20110152292-A1 | SALTS COMPRISING A PYRIMIDINECARBOXYLIC ACID DERIVATIVE FOR COSMETIC USE | NUDT1, PPIP5K2, ENPP1 | HSP90AA1 3995/4885KDM4E 3785/4885TKT 329/4885 |
| US-20090220441-A1 | Nanoparticulate UV Protectant With Silicon Dioxide Coating | CUTA, SUCLG1, TYR | HSP90AA1 325/4885KDM4E 2443/4885TKT 3320/4885 |
| US-12466825-B2 | Synthesis of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | HSP90AA1 4258/4885KDM4E 2685/4885TKT 1477/4885 |
| US-20120022072-A1 | PTERIN ANALOGS | DHFR, MTHFD2, HMBS | HSP90AA1 1559/4885KDM4E 4678/4885TKT 299/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | HSP90AA1 3470/4885KDM4E 4105/4885TKT 3459/4885 |
| US-20020055532-A1 | UV-B filter | CBR1, UQCRB, H1-0 | HSP90AA1 2876/4885KDM4E 2453/4885TKT 3421/4885 |
| US-20060039937-A1 | Composition having antioxidant properties | GPX4, GPX1, CAT | HSP90AA1 2988/4885KDM4E 2617/4885TKT 3446/4885 |
| US-12441736-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | HSP90AA1 298/4885KDM4E 1251/4885TKT 238/4885 |
| US-20090196894-A1 | Self Tanning Composition | C9, KRT18, F12 | HSP90AA1 2551/4885KDM4E 373/4885TKT 430/4885 |
| US-20180221426-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | CAT, CUTA, GPX1 | HSP90AA1 979/4885KDM4E 2485/4885TKT 835/4885 |
| US-20230121955-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | KRAS, NRAS, HRAS | HSP90AA1 2401/4885KDM4E 3001/4885TKT 2806/4885 |
| US-20240173328-A1 | COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | KRAS, NRAS, HRAS | HSP90AA1 2401/4885KDM4E 3001/4885TKT 2806/4885 |
| US-20220213101-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSP90AA1 3392/4885KDM4E 4087/4885TKT 3311/4885 |
| US-20090246158-A1 | ANTIOXIDANTS | LPO, GPX1, GPX4 | HSP90AA1 1943/4885KDM4E 4182/4885TKT 1671/4885 |
| US-20220133828-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | CAT, CUTA, GPX1 | HSP90AA1 979/4885KDM4E 2485/4885TKT 835/4885 |
| US-20200261517-A1 | METHODS AND COMPOSITIONS RELATING TO MICROBIAL TREATMENT AND DIAGNOSIS OF DISORDERS | FAH, LIPC, ASAH2 | HSP90AA1 1582/4885KDM4E 4398/4885TKT 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.